

Sinohealth Hldg 中康控股

中康控股有限公司

Sinohealth Holdings Limited

(Incorporated in the Cayman Islands with limited liability)

(於開曼群島註冊成立的有限公司)

Stock Code 股份代號: 2361

2023 INTERIM REPORT 中期報告





Contents

目錄

2	Corporate Information	公司資料
6	Core Financial and Operational Data	核心財務及運營數據
7	Financial Summary	財務摘要
8	Management Discussion and Analysis	管理層討論及分析
45	Corporate Governance and Other Information	企業管治及其他資料
57	Interim Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income	中期簡明綜合損益及其他全面收益表
59	Interim Condensed Consolidated Statement of Financial Position	中期簡明綜合財務狀況表
61	Interim Condensed Consolidated Statement of Changes in Equity	中期簡明綜合權益變動表
63	Interim Condensed Consolidated Statement of Cash Flows	中期簡明綜合現金流量表
67	Notes to the Interim Condensed Consolidated Financial Information	中期簡明綜合財務資料附註
98	Definitions	釋義

2 CORPORATE INFORMATION 公司資料

BOARD OF DIRECTORS

Executive Directors

Mr. Wu Yushu (*Chairman*)

Ms. Wang Lifang

Non-executive Director

Mr. Fu Haitao

Independent Non-executive Directors

Ms. Wang Danzhou

Ms. Du Yilin

Mr. Wei Bin

AUDIT COMMITTEE

Mr. Wei Bin (*Chairman*)

Ms. Wang Danzhou

Ms. Du Yilin

REMUNERATION COMMITTEE

Ms. Wang Danzhou (*Chairperson*)

Ms. Du Yilin

Ms. Wang Lifang

NOMINATION COMMITTEE

Mr. Wu Yushu (*Chairman*)

Ms. Du Yilin

Ms. Wang Danzhou

AUTHORISED REPRESENTATIVES

Mr. Wu Yushu

Ms. Zhang Xiao

JOINT COMPANY SECRETARIES

Ms. Yi Xuhui

Ms. Zhang Xiao *ACG, HKACG*

董事會

執行董事

吳鬱抒先生(*主席*)

王莉芳女士

非執行董事

付海濤先生

獨立非執行董事

王丹舟女士

杜依琳女士

魏斌先生

審核委員會

魏斌先生(*主席*)

王丹舟女士

杜依琳女士

薪酬委員會

王丹舟女士(*主席*)

杜依琳女士

王莉芳女士

提名委員會

吳鬱抒先生(*主席*)

杜依琳女士

王丹舟女士

授權代表

吳鬱抒先生

張瀟女士

聯席公司秘書

易旭暉女士

張瀟女士 *ACG · HKACG*

REGISTERED OFFICE IN THE CAYMAN ISLANDS

89 Nexus Way
Camana Bay
Grand Cayman KY1-9009
Cayman Islands

開曼群島註冊辦事處

89 Nexus Way
Camana Bay
Grand Cayman KY1-9009
Cayman Islands

PRINCIPAL PLACE OF BUSINESS IN THE PRC

Room 1111, No.5 Wangjiang Second Street
Huangge Town, Nansha District
Guangzhou City
Guangdong Province
PRC

中國主要營業地點

中國
廣東省
廣州市
南沙區黃閣鎮
望江二街5號1111房

PRINCIPAL PLACE OF BUSINESS IN HONG KONG

40/F, Dah Sing Financial Centre
No. 248 Queen's Road East
Wanchai
Hong Kong

香港主要營業地點

香港
灣仔
皇后大道東248號
大新金融中心40樓

CAYMAN ISLANDS PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE

Ogier Global (Cayman) Limited
89 Nexus Way
Camana Bay
Grand Cayman KY1-9009
Cayman Islands

開曼群島股份過戶登記總處

Ogier Global (Cayman) Limited
89 Nexus Way
Camana Bay
Grand Cayman KY1-9009
Cayman Islands

HONG KONG SHARE REGISTRAR AND TRANSFER OFFICE

Boardroom Share Registrars (HK) Limited
2103B, 21/F
148 Electric Road
North Point
Hong Kong

香港證券登記處

寶德隆證券登記有限公司
香港
北角
電氣道148號
21樓2103B室

4 CORPORATE INFORMATION 公司資料

COMPLIANCE ADVISER

Giraffe Capital Limited
3/F, 8 Wyndham Street
Central
Hong Kong

LEGAL ADVISERS

As to Hong Kong law
Jingtian & Gongcheng LLP
Suites 3203-3207
32/F, Edinburgh Tower
The Landmark
15 Queen's Road Central
Hong Kong

As to PRC law
Jingtian & Gongcheng
45/F, K. Wah Centre
1010 Huaihai Road (M)
Shanghai
China

AUDITOR

Ernst & Young
Certified Public Accountants
Registered Public Interest Entity Auditor
27/F, One Taikoo Place
979 King's Road
Quarry Bay
Hong Kong

合規顧問

智富融資有限公司
香港
中環
雲咸街8號3樓

法律顧問

關於香港法例
競天公誠律師事務所有限法律責任合夥
香港
皇后大道中15號
置地廣場
公爵大廈32樓
3203-3207室

關於中國法律
競天公誠律師事務所
中國
上海市
淮海中路1010號
嘉華中心45層

核數師

安永會計師事務所
執業會計師
註冊公眾利益實體核數師
香港
鰂魚涌
英皇道979號
太古坊1座27樓

PRINCIPAL BANKS

Ping An Bank Guangzhou Huangpu Avenue Branch
1/F, Fulilong Square
No. 76 Huangpu Avenue West
Tianhe District
Guangzhou City
Guangdong Province
PRC

China Everbright Bank Guangzhou Huangpu Avenue West
Branch
Suit 02, 1/F, Qinjian Mansion
No.118 Huangpu Avenue
Tianhe District
Guangzhou City
Guangdong Province
PRC

STOCK CODE

2361

COMPANY'S WEBSITE

ir.sinohealth.cn

主要往來銀行

平安銀行廣州黃埔大道支行
中國
廣東省
廣州市
天河區
黃埔大道西76號
富力盈隆廣場首層

中國光大銀行廣州黃埔大道西支行
中國
廣東省
廣州市
天河區
黃埔大道118號
勤建大廈首層02商舖

股份代號

2361


公司網址

ir.sinohealth.cn


6 CORE FINANCIAL AND OPERATIONAL DATA 核心財務及運營數據

Financial performance 財務表現


REVENUE 收入




GROSS PROFIT 毛利



NET PROFIT 純利



REVENUE BY APPLICATION SCENARIOS 按應用場景劃分的收入




Core competence 核心競爭力

Data collection network 數據採集網路

Partnering Pharmacies and Participant Networks
合作藥店及參與者網絡

(1H FY 2022 vs 1H FY 2023)



Data collection network covers more than 70,000 pharmacy stores spanning 339 cities in 30 provinces, of which 80% can assess data in real time and more than 80% of the order-related data can be obtained instantly. The GMV of our partnering pharmacies amounted to approximately RMB149.9 billion, accounting for approximately 31.1% of the total sales amount of retail pharmacies in China in 2022.

數據採集網路覆蓋藥店門店數超過7萬家，分佈30個省339個城市，可即時獲取數據門店佔比80%，即時獲取訂單級數據超過80%。合作門店GMV約1499億元，佔2022年中國醫藥零售企業銷售總額的31.1%

The storage capacity of the database has exceeded 32TB 自有數據庫存儲量已超過32TB

Smart Health Management Cloud reached over 160 hospitals and 650 private physical examination centers, More than 200,000 physical examinations data have been processed and analyzed.

智慧健康管理雲已觸達超過160家醫院、650家民營體檢中心，處理和分析超過20萬例體檢數據

Smart Medical Cloud has partnered with six top-tier hospitals and 38 clinical departments in China, serving more than 200,000 patients.

智慧醫療雲與6家頂級醫院、38個臨床科室達成合作，服務的患者超過20萬

Big data governing technology 大數據治理技術

We have established a whole life cycle data governance system and data security guarantee system have been

建立全生命週期數據治理體系及數據安全保障體系

We have created knowledge graphs based on evidence-based medicine and biomedical sciences, has covered 7,764 disease categories.

構建以循證醫學和生物醫學為基礎的知識圖譜，已覆蓋7,764種疾病病種

The machine cleaning rate exceeds 97%, the data accuracy exceeds 99%, and the monthly processing and analysis data exceeds 210 million pieces.

機器清洗率超97%，數據準確率超99%，月處理分析數據超2.1億條

Based on the data scale, data governance ability and artificial intelligence analysis model, we were selected into the list of Guangzhou Big Data Artificial Intelligence Enterprise Database and Guangzhou's most promising artificial intelligence enterprises, and became a strategic partner of Shenzhen Data Exchange.

基於數據規模、數據治理能力及人工智能分析模型，入選廣州大數據人工智能企業庫、廣州最具發展潛力人工智能企業榜單，成為深圳數據交易所戰略級合作夥伴

Ecological industrial platform 生態化的產業平台

Through the Healthcare Link platform, we have accumulated a community of over 1,000,000 professionals in the healthcare industry, and successfully aggregated more than 1,300 high-quality upstream suppliers from both domestic and international markets and over 4,000 downstream pharmacy retailers, covering over 270,000 pharmacy stores.

通過Healthcare Link平台沉澱超百萬健康產業從業者，上游聚合1300多家國內外優質供應商，下游聚合4000多家醫藥零售藥店企業，覆蓋藥店門店數超過27萬間

Over the past 16 years, CPEO has connected approximately 60,000 key industry decision makers in a single conference.

歷經16年，西普會單屆最高連接約6萬名產業關鍵決策者

The media platform matrix has accumulated nearly one million health industry professionals

媒體平台矩陣積累近百萬健康產業專業人士

Talent team and Data security 人才團隊及數據安全

Professional talent reserve: medical professionals accounted for 18%, medical professionals accounted for 13%, computer science professionals accounted for 22%

專業人才儲備：醫學專業人才佔比18%、醫藥專業人才佔比13%、計算機科學專業人員佔比22%

Research and development personnel: 241, accounting for 34.5%

研發人員：241名，佔比34.5%

Obtain ISO certification for information technology, information security and Privacy information

獲得信息技術、信息安全及隱私信息ISO認證

A number of information systems have passed the national information security level protection (Level 3) assessment and record

多個信息系統通過國家信息安全等級保護（三級）的測評和備案

FINANCIAL SUMMARY 7

財務摘要

For the six months ended 30 June

截至6月30止六個月

		2023 (Unaudited) 2023年 (未經審核) RMB'000 人民幣(千元)	Percentage of total revenue 佔總收入 百分比	2022 (Unaudited) 2022年 (未經審核) RMB'000 人民幣(千元)	Percentage of total revenue 佔總收入 百分比	Year-on-year change 同比變動
Revenue	收入	144,950	100%	121,209	100%	19.6%
Smart Decision Cloud	智慧決策雲	72,073	49.7%	54,351	44.8%	32.6%
Smart Retail Cloud	智慧零售雲	43,834	30.2%	46,257	38.2%	-5.2%
Smart Medical Cloud	智慧醫療雲	23,314	16.1%	19,964	16.5%	16.8%
Smart Health Management Cloud	智慧健康管理雲	5,729	4.0%	637	0.5%	799.4%
Cost of sales	銷售成本	69,768		64,558		8.1%
Gross profit	毛利	75,182		56,651		32.7%
Net profit	純利	46,970		5,287		788.4%

8 MANAGEMENT DISCUSSION AND ANALYSIS 管理層討論及分析

BUSINESS REVIEW

We are a leading service provider in China offering digital intelligence solutions based on big data, artificial intelligence and cloud computing to improve efficiency in the life sciences sector. Through our healthcare industry vertical cloud platform, we offer a comprehensive range of products and services to meet the digitalisation needs of key players in the healthcare industry. We have established a healthcare industry vertical cloud platform covering “Smart Decision Cloud, Smart Retail Cloud, Smart Medical Cloud, Smart Health Management Cloud, Smart Clinic Cloud and Smart Insurance Cloud”, which provides patient-centered integrated solutions for life-cycle health management integrating the elements of “prevention, treatment, maintenance, body and mind”. Our healthcare industry vertical cloud platform has the following key features:

1) Industry-leading data collection network

The Group has industry-leading master and retail market insight databases in terms of data type and data size. We have established an extensive data collection network by focusing on pharmaceutical retailing, physical examination, clinical diagnosis and treatment scenarios that cover all endpoints of patients. With our unremitting efforts, we maintain a leading position in the market in terms of data collection network, data size and data quality.

業務回顧

我們系中國領先的基於大數據、人工智能和雲計算，為生命科學領域效率提升提供數智化解決方案的服務提供商。我們通過健康產業垂直雲平台，為健康產業主要參與者提供全面的產品和服務，以滿足其數字化的需求。我們設立了「智慧決策雲、智慧零售雲、智慧醫療雲、智慧健康管理雲、智慧診所雲、智慧保險雲」的健康產業垂直雲平台，以患者為中心，向客戶提供貫穿「防、治、養、身、心」的全生命週期健康管理的綜合解決方案，我們的健康產業垂直雲平台具有如下主要特點：

1) 行業領先的數據採集網絡

本集團擁有在數據種類和數據規模方面均處於行業領先地位的主數據庫和零售市場洞察數據庫。我們專注於醫藥零售、健康體檢、臨床診斷及治療場景等覆蓋患者全終端觸點建立了廣泛的數據採集網絡，通過我們的不懈努力，我們數據採集網絡、數據規模和數據質量繼續處於市場領先地位。

MANAGEMENT DISCUSSION AND ANALYSIS 9

管理層討論及分析

As at 30 June 2023, the Group developed 38 master databases of healthcare industry covering data relating to industry regulation, medicine, pharmacy and life sciences, thus building a comprehensive master data labeling system and forming knowledge graphs. We have stored and analysed more than 32TB of data. The number of pharmaceutical retailers covered by our data collection network through the SIC and CMH model partnership exceeded 1,200. Our partnering pharmacies covers more than 70,000 stores, representing a year-on-year increase of 10.8% as compared to the first half of 2022, spanning 339 cities in 30 provincial administrative regions, of which 80% can assess data in real time and more than 80% of the order-related data can be obtained instantly. Based on our estimation, the GMV of our partnering pharmacies amounted to approximately RMB149.9 billion, accounting for approximately 31.1% of the total sales amount of retail pharmacies in China in 2022. For the six months ended 30 June 2023, our Health Management Cloud reached over 160 hospitals and 650 private physical examination centers in China, and we have processed and analyzed the physical examination data of more than 200,000 physical examination users. Our Smart Medical Cloud has partnered with six top-tier hospitals and 38 clinical departments in China, serving a total of over 200,000 patients.

截至2023年6月30日，本集團開發了38個主數據庫，涵蓋行業監管、醫學、藥學和生命科學在內的健康行業主數據庫，構建了完整的主數據標籤體系，並形成了知識圖譜。我們存儲及分析累積的主要數據超過32TB。我們通過SIC和CMH模式合作的數據採集網絡所覆蓋的醫藥零售企業數超過1200家，合作藥店覆蓋門店數超過70,000家，同比2022年上半年增長約10.8%，分佈30個省級行政區域，339個城市，我們可即時獲取數據門店佔比80%，即時獲取訂單級數據超過80%。根據我們估計，我們的合作藥店GMV約為人民幣1,499億元，約佔2022年中國零售藥店銷售總額的31.1%。截至2023年6月30日止六個月，我們的健康管理雲已觸達超過160家醫院、650家民營體檢中心，處理和分析超過20萬名體檢用戶的體檢數據，我們的智慧醫療雲與中國6家頂級醫院、38個臨床科室達成了合作，合計服務的患者則超過20萬名。

10 MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

The Group attaches great importance to data security and privacy management, has always regarded data security as the lifeline of development, and ensures full-process protection for data collection, cleansing, treatment, storage and application. We have constructed a data security and privacy management system in terms of compliance management, data security architecture, division of authority, operation and maintenance, disaster recovery and personal safety, which is updated and improved in accordance with laws and regulations as amended from time to time, in order to ensure the security and compliance of the Group's core data assets in their entire lifecycle.

本集團高度注重數據安全及隱私管理，始終把數據安全視為發展的生命線，對數據採集、清洗、治理、存儲、應用等進行全流程保障。我們從合規管理、數據安全架構、權限劃分、運維和災備、人員安全等方面構建數據安全及隱私管理體系，並根據不時修訂的法律法規進行更新與完善，以保障集團核心數據資產全生命週期的安全及合規。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

The following table sets forth certain key information regarding our data collection network for the periods indicated.

下表載列於所示期間有關我們數據採集網絡的若干重要資料。

		For the six months ended		
		30 June		
		截至6月30止六個月		
		2023	2022	Year-on-year
		2023年	2022年	change
				同比變動
Number of Partnering Pharmaceutical Retailers	合作的醫藥零售企業數	1,262	1,257	0.4%
Number of Stores Covered by Partnering Pharmacies	合作藥店覆蓋的門店數	70,089	63,234	10.8%
Number of Staff Using SIC Mobile App ('000)	使用SIC移動應用程序的員工人數(千人)	223	192	16.1%
Number of Active Pharmacy Staff Using SIC Mobile App ('000)	使用SIC移動應用程序的活躍藥店員工(千人)	50	43	16.3%
Number of Pharmacy Consumers Managed by Pharmacies through SIC ('000)	藥店透過SIC管理的藥店消費者(千人)	329,092	231,237	42.3%
Number of Active Pharmacy Consumers Managed by Pharmacies through SIC ('000)	藥店透過SIC管理的活躍藥店消費者(千人)	38,790	26,791	44.8%
Total Number of Retail Sales Entries Collected through SIC (million)	通過SIC收集的零售銷售條目總數(百萬)	176	132	33.3%

12 MANAGEMENT DISCUSSION AND ANALYSIS 管理層討論及分析

2) Industry-leading big data treatment technology

The Group has industry-leading big data treatment technology in big data field of healthcare industry chain. We have established a PaaS layer technology cluster that covers the entire healthcare industry chain. Based on technologies such as big data, artificial intelligence and cloud computing, we have established an advanced treatment system for the entire lifecycle of data integration, storage, modeling, analysis, mining and circulation. We have also constructed a secure system leveraging on trusted matrix, de-identification, traceability and other technical means, and outperform the industry average in terms of data scale, data granularity, data cleansing rate, processing efficiency, coverage, accuracy, diversity and governance.

We have also created knowledge graphs based on evidence-based medicine and biomedical sciences which, through a deep learning process, can be automatically associated with the corresponding health indicators, symptoms, diagnostic terminologies, treatment or daily care recommendations for various diseases. As at 30 June 2023, our knowledge graphs covered 7,764 diseases.

We have very strong data processing capabilities. As at 30 June 2023, our data cleansing rate by the middleware exceeded 97%, with a data accuracy rate of over 99%, and we processed and analyzed more than 210 million pieces of data per month. This enables us to efficiently treat large amounts of data in a short period of time and ensures the accuracy and reliability of the data, thus allowing us to build a structured, standardised and systematically analysable data system.

2) 行業領先的大數據治理技術

本集團在健康產業鏈大數據領域擁有行業領先的大數據治理技術。我們建立了覆蓋健康產業鏈的PaaS層技術集群，並基於大數據、人工智能、雲計算等技術在數據集成、存儲、建模、分析、挖掘和流通等全生命週期建立了高水平治理體系，結合可信空間、去標識化、溯源等技術手段構建安全體系，我們在數據規模、數據顆粒度、數據清洗率、處理效率、覆蓋面、準確性、多樣性和治理程度等方面優於行業平均水平。

我們亦創建了以循證醫學和生物醫學為基礎的知識圖譜，並經過深度學習程序，可自動與各種疾病項下相應的健康指標、症狀、診斷術語、治療或日常護理建議等相關聯。截至2023年6月30日，我們的知識圖譜已覆蓋7,764個的疾病病種。

我們的數據處理能力非常強大。截至2023年6月30日，我們的數據機器清洗率超過97%，數據準確率超過99%，我們處理分析的數據記錄超過2.1億條/月。這使得我們能夠在短時間內高效治理大量數據，並且保證了數據的準確性和可靠性，從而幫助我們建立結構化、標準化和可系統分析的數據體系。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

Our technology and data platform infrastructure, Sinohealth-Engine, consists of data technology, AI technology, cloud computing and knowledge insights, which continue to accumulate with the expansion of application scenarios. We can rapidly acquire, cleanse, analyze and use data, and can constantly optimise and expand our products through data treatment, analysis, interpretation and prediction, thus enabling us to provide data-driven solutions and digital support for players in the healthcare industry chain in various application scenarios.

With focus on independent innovation and intellectual property protection, we continue to maintain our investment in research and development in the three areas of big data technology, artificial intelligence and cloud computing, which further strengthens our technological innovation capability as well as our ability to transform technological achievements to help our customers better realise their business objectives and connect the industrial ecosystem. During the Reporting Period, we obtained 8 assessment certifications. We have 10 core patents and 120 core software copyrights approved by the China National Intellectual Property Administration. Our Smart Medical Cloud business segment has published four papers in collaboration with other participants in the healthcare industry, with core employees of our Smart Medical Cloud business as co-authors.

我們的技術及數據平台基建 Sinohealth-Engine 由數據技術、AI 技術、雲計算及知識洞見構成，並隨著應用場景的拓展而持續累積。我們可以快速地獲取、清洗、分析和使用數據，通過對數據的治理、分析、解讀和預測，可以不斷優化和拓展我們的產品，從而推動我們為健康產業鏈上的參與者提供各種應用場景的數據驅動解決方案及數字化支持。

我們注重自主創新和保護知識產權，繼續保持在大數據技術、人工智能和雲計算三方面的研發投入，這進一步加強了我們技術創新能力以及科技成果轉化能力，幫助客戶更好地實現經營目標和連接產業生態。報告期內，我們獲得的測評認證有 8 項。我們擁有經國家知識產權局批准的核心專利有 10 項，核心軟件著作權有 120 項。我們智慧醫療雲業務板塊與健康產業其他參與者合作發表的論文有 4 篇，我們智慧醫療雲業務的核心員工為作者之一。

14 MANAGEMENT DISCUSSION AND ANALYSIS 管理層討論及分析

In addition, we have been recognised as a High-Tech Enterprise in Guangdong Province, a Specialised and Innovative Small and Medium-sized Enterprise in Guangdong Province, a Headquarter Enterprise of Guangzhou, an Innovative Small and Medium-sized Enterprise in Guangzhou, a Big Data Artificial Intelligence Enterprise in Guangzhou, and the Most Promising Artificial Intelligence Enterprise in Guangzhou. These accolades are a testament to the comprehensive acknowledgment of the Group's technological innovation, product quality, service excellence, and promising market prospects by relevant government departments and esteemed industry associations, and serve as a driving force for the Group to maintain its unwavering commitment to technology as the foundation and quality as the lifeblood. We will strive to advance our expertise in the fields of big data, artificial intelligence, and cloud computing, fully harness digital value, maintain market competitiveness, and facilitate the intelligent transformation of participants in the healthcare industry, thereby providing multi-level healthcare products and services for patients and leading industry development through innovation.

同時，我們相繼入選廣東省高新企業、廣東省專精特新中小企業、廣州市總部企業、廣州市創新性中小企業、廣州市大數據人工智能企業、廣州市最具發展潛力人工智能企業等，這充分表現了政府有關部門及行業權威機構對本集團在技術創新、產品品質、服務水平、市場前景等方面的充分認可，同時也鞭策本集團始終堅持技術為根本、品質為生命，努力在大數據、人工智能及雲計算領域精進技術，充分發揮數字價值，保持市場競爭力，及助力健康行業參與者智能化轉型，為患者提供多層次的健康產品及服務，創新引領行業發展。

3) Unique ecosystem-based healthcare industry platform

The Group has established a global ecosystem-based healthcare industry platform. This platform brings together leading enterprises and institutions from various sectors, including branded pharmaceutical companies, pharmaceutical retailers, innovative pharmaceutical companies, capital giants, healthcare product manufacturers and distributors, medical device companies, pharmaceutical commercial entities, pharmaceutical research organisations, healthcare service providers, medical institutions, data and new technology companies, comprehensive healthcare and wellness service providers, and financial and insurance institutions in China and abroad. Through this industry platform, we offer forward-thinking and systematic exchanges of ideas and information, facilitating multi-dimensional resource integration and precise interactions from strategy to execution.

3) 獨特的生態化健康產業平台

本集團打造了全球性的生態化健康產業平台。我們的平台匯聚了國內外包括品牌藥企、醫藥零售企業，創新藥企、產業資本、保健品產銷企業、醫療器械企業、醫藥商業、醫藥研發機構、健康服務機構、醫療機構、數據及新技術企業、健康養生綜合服務機構、金融及保險等領域主流企業與機構，通過產業平台，我們提供前瞻性、系統性的思想與信息交流，從策略到戰略的多元資源對接和精準交互。

16 MANAGEMENT DISCUSSION AND ANALYSIS 管理層討論及分析

As at 30 June 2023, through our Healthcare Link data platform, we have accumulated a community of over 1,000,000 professionals in the healthcare industry, and successfully aggregated more than 1,300 high-quality upstream suppliers from both domestic and international markets and over 4,000 downstream pharmacy retailers, covering over 270,000 pharmacy stores. After being held for 16 years, CPEO has become a forward-looking industry platform with leading position in China's healthcare industry in terms of specifications, scale and influence. A single conference can connect over 60,000 elite professionals from various entities within the healthcare industry. PHCF has been recognised by the Hainan Provincial Department of Commerce as a 2023 provincial-level project in Hainan Province. Additionally, our media platform matrix has accumulated nearly one million professionals in various fields, including pharmaceutical retail experts, pharmaceutical and medical device manufacturers, pharmacists, physicians, medical experts and industry investors.

We are committed to continuously creating iconic and leading quality content for the industry, aiming to build a comprehensive, efficient, and trend-setting ecosystem in the healthcare industry to provide more precise and high-value opportunities for cooperation in the industry.

截至2023年6月30日，我們通過Healthcare Link數據平台沉澱超過100萬健康產業從業者，上游聚合1300多家國內外優質供應商，下游聚合4000多家醫藥零售藥店企業，覆蓋藥店門店數超過27萬間。歷經16年，西普會已經成為中國健康產業規格領先、規模領先、影響力領先的前瞻性產業平台，單屆連接超過6萬名健康產業各主體精英。西鼎會獲得海南省商務廳認定為海南省2023年省級項目。此外，我們的媒體平台矩陣積累的醫藥零售專家、藥械廠商專家、藥師、醫師、醫學專家、行業投資者等領域的專業人士合計近百萬。

我們將繼續為行業發展創造更具標桿性和引領性的優質內容，打造一個全覆蓋、高效連接、引領趨勢的大健康產業生態，提供更精確、更高價值的產業連接機會。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

During the Reporting Period, benefiting from the Group's industry-leading data collection network and big data treatment technology, as well as its unique ecological healthcare industry platform, Zhongkang Technology, our wholly-owned subsidiary, entered into a strategic cooperation agreement with Shenzhen Data Exchange, pursuant to which the parties will jointly explore a new path of close integration of data circulation infrastructure and data trading, and play an exemplary role in promoting in-depth cooperation in big data business for the medical and healthcare industry nationwide. It also indicated that the Group's strength and influence in big data treatment in the medical and healthcare industry was widely recognized, and further strengthened the Group's leading position in the field of big data in the medical and healthcare industry.

In the future, we will continuously expand our leading edge and continue to promote the in-depth application of big data, artificial intelligence, cloud computing and other technologies in the field of healthcare science and technology to advance the digitalization of the healthcare industry.

報告期內，得益於本集團在行業領先的數據採集網絡與大數據治理技術、及獨特的生態化健康產業平台，我們的全資附屬公司中康科技與深圳數據交易所訂立了戰略合作協議，雙方將共同探索數據流通基礎設施與數據交易緊密融合的新路徑，以點帶面推進全國範圍內醫療健康產業大數據業務的深入合作。這亦標誌著本集團在醫療健康產業領域的大數據治理實力和影響力得到廣泛認可，也進一步加強了本集團在醫療健康產業大數據領域的領先地位。

未來我們將持續擴大我們的領先優勢，繼續推進大數據、人工智能、雲計算等技術在健康科技領域的深度應用，推進健康產業數字化的發展。

18 MANAGEMENT DISCUSSION AND ANALYSIS 管理層討論及分析

BUSINESS OF THE GROUP

During the Reporting Period, our revenue was mainly derived from (1) Smart Decision Cloud; (2) Smart Retail Cloud; (3) Smart Medical Cloud; and (4) Smart Health Management Cloud.

For the six months ended 30 June 2023, the number of corporate customers partnered with the Group was 842, an increase of 35.2% compared to 623 for the same period in 2022, in which the repurchase rate of top class pharmaceutical and medical device corporate customers reached 94.7%

The Group's revenue increased by approximately 19.6% from approximately RMB121.2 million for the six months ended 30 June 2022 to approximately RMB145.0 million for the six months ended 30 June 2023. The Group's gross profit for the six months ended 30 June 2023 amounted to approximately RMB75.2 million, representing an increase of approximately 32.7% as compared to approximately RMB56.7 million for the six months ended 30 June 2022. The Group's gross profit margin increased by 5.2 percentage points from approximately 46.7% for the six months ended 30 June 2022 to approximately 51.9% for the corresponding period of 2023. The Group's net profit margin (calculated based on profit for the period) increased by 28.0 percentage points from approximately 4.4% for the six months ended 30 June 2022 to approximately 32.4% for the same period in 2023.

本集團的業務

於報告期內，我們主要從(1)智慧決策雲；(2)智慧零售雲；(3)智慧醫療雲；及(4)智慧健康管理雲產生收入。

截至2023年6月30日止六個月，本集團的企業級客戶合作數量為842家，較2022年同期的623家增長了35.2%，其中，頂尖製藥及醫療設備企業客戶的復購銷售率達到了94.7%。

本集團的收益由截至2022年6月30日止六個月約人民幣121.2百萬元增加約19.6%至截至2023年6月30日止六個月約人民幣145.0百萬元。本集團的毛利截至2023年6月30日止六個月約人民幣75.2百萬元，較截至2022年6月30日止六個月約人民幣56.7百萬元增加約32.7%。本集團的毛利率由截至2022年6月30日止六個月的約46.7%增加5.2個百分點至2023年同期的約51.9%。本集團的淨利潤率(以期間溢利計算)由截至2022年6月30日止六個月的約4.4%增加28.0個百分點至2023年同期的約32.4%。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

The following table sets forth a breakdown of our revenue by application scenario for the periods indicated:

下表載列我們於所示期間按應用場景劃分的收入明細：

		For the six months ended 30 June 截至6月30止六個月				Year-on-year change 同比波動
		2023 2023年 (Unaudited) (未經審核)		2022 2022年 (Unaudited) (未經審核)		
		RMB'000 人民幣 (千元)	% as total revenue 佔總收入 百分比	RMB'000 人民幣 (千元)	% as total revenue 佔總收入 百分比	(%)
Smart Decision Cloud	智慧決策雲	72,073	49.7%	54,351	44.8%	32.6%
Smart Retail Cloud	智慧零售雲	43,834	30.2%	46,257	38.2%	-5.2%
Smart Medical Cloud	智慧醫療雲	23,314	16.1%	19,964	16.5%	16.8%
Smart Health Management Cloud	智慧健康管理雲	5,729	4.0%	637	0.5%	799.4%
Total	總計	144,950	100.0%	121,209	100.0%	19.6%

20 MANAGEMENT DISCUSSION AND ANALYSIS 管理層討論及分析

SMART DECISION CLOUD

In the context of efficient decision-making for pharmaceutical and medical device companies, our core competency lies in integrating the entire chain of pharmaceutical and medical device products that covers research and development, production, distribution, promotion and end-user retail, as well as the entire lifecycle of health management. We provide our clients with an integrated Smart Decision Cloud solution, empowering pharmaceutical and medical device companies with efficient decision-making capabilities and improving the quality of their decision-making processes.

By utilising our SaaS product series under the Smart Decision Cloud, our clients are able to achieve online operation of pharmacies, thereby facilitating the process of digital transformation. The Group can provide detailed data query and data insight through multi-dimensional and extensive data analysis, and utilise different scenario empowerment and modeling tools to achieve standardised, normalised, intelligent and visualised management of pharmaceutical and medical device product flow data, thereby facilitating the decision-making process for new drug research and development, clinical trials, and production and marketing. In addition, we can assist our clients in obtaining information on midstream and downstream channels, retailers, market trends, industry development, as well as patient needs and behavior. By doing so, we can help our clients adjust their production and marketing strategies proactively, thereby improving the market position and market share of products. During the Reporting Period, our Smart Decision Cloud SaaS significantly increased customer stickiness, thus expanding our commercial opportunities.

智慧決策雲

基於製藥及醫療設備企業高效決策的場景下，我們核心能力在於打通藥械產品從研發、生產、流通、推廣、終端零售的全鏈條，以及所處的健康管理全生命週期，為客戶提供一體化智慧決策雲綜合解決方案，賦能製藥及醫療設備企業高效決策能力，提高決策質量。

客戶通過使用我們的智慧決策雲的系列SaaS產品，可以實現藥店線上化，從而助力數字化轉型的進程。本集團可以提供詳細級別的數據查詢、數據洞察，通過多角度、海量數據分析，並利用不同的場景賦能和建模工具，實現對藥械產品流向數據的標準化、規範化、智能化和可視化管理，從而支持其新藥研發、臨床試驗及生產營銷的決策進程。此外我們可以幫助其掌握中下游渠道與零售商信息，市場信息和行業動態，及患者需求和行為，輔助客戶積極調整生產營銷策略，從而能夠提升產品市場地位和市場份額。報告期內，我們的智慧決策雲SaaS顯著提升了客戶粘性，從而增加我們的商業化機會。

MANAGEMENT DISCUSSION AND ANALYSIS 21

管理層討論及分析

To better support the digital transformation of pharmaceutical and medical device companies, we also provide efficient digital decision-making professional services to our clients. The Group conducts in-depth analysis of the unique characteristics of pharmaceutical and medical device products across various stages, from research and development, production, distribution to marketing, and provides a wide range of comprehensive insight research, data analysis and visualisation tools to help pharmaceutical and medical device companies quickly obtain key information from each stage of the product lifecycle. By doing so, our services enable our clients to optimise and manage their supply chain, improve their decision-making capabilities and efficiency, and minimise their decision-making costs. We also utilise digital technologies to assist our clients in conducting market analysis, forecasting, and monitoring, allowing them to develop and adjust their sales strategies in a proactive and informed manner, thereby improving the marketing effectiveness and increasing market share.

In addition, we leverage industry ecosystem platforms such as CPEO, the Pharmaceutical Innovation Ecological Conference, the Healthcare Industry Capital Summit and the Healthcare Industry Think Tank to bring together key players in the healthcare industry. Through these platforms, we facilitate forward-thinking and systematic exchange of ideas and information, as well as multi-dimensional resource integration and precise interaction in respect of strategies and tactics. This further enhances the efficiency of inter-industry connectivity, promotes optimal resource allocation, and creates a win-win service model for us and our clients, ultimately empowering our overall business.

為了更好助力製藥及醫療設備企業實現數字化轉型，我們亦向客戶提供高效的數字決策專業服務。本集團充分分析藥械產品的從研發、生產、流通到營銷等各個環節的特點，提供多種綜合洞察研究和數據分析和可視化工具，幫助製藥及醫療設備企業快速獲取各個環節的關鍵信息，從而實現供應鏈的優化和管管理，提高客戶決策的能力和效率，最大程度的降低決策成本。我們亦以數字技術助力客戶進行市場分析、預測和監控，從而制定和積極調整合理的銷售策略，從而提高營銷效果，提升市場份額。

同時，我們亦通過產業生態平台，例如通過西普會、醫藥創新生態大會、健康產業資本峰會和健康產業智庫等平台聚焦健康產業主要精英，為客戶前瞻性、系統性的思想與信息交流、從策略到戰略的多元資源對接和精準交互，進一步提高產業間互通互聯效率，促進資源優化配置，從而實現我們與客戶雙贏的服務模式，為我們的整體業務賦能。

22 MANAGEMENT DISCUSSION AND ANALYSIS 管理層討論及分析

For the six months ended 30 June 2023, 461 corporate customers purchased the Group's Smart Decision Cloud services, as compared to 331 customers in the first half of 2022, representing a year-on-year increase of approximately 39.3%. In the first half of 2023, the overall repurchase rate of our Smart Decision Cloud corporate customers was 92.2%.

During the Reporting Period, our revenue from the provision of Smart Decision Cloud services recorded a year-on-year increase of 32.6% from RMB54.4 million for the six months ended 30 June 2022 to RMB72.1 million for the six months ended 30 June 2023, which was mainly due to the increase in revenue generated from new orders arising from the expansion of our data insight business and the market acceptance of our SaaS products.

SMART RETAIL CLOUD

Leveraging on the unique advantage of over 70,000 partnering pharmacies, the Group has established a "one-stop" data collection platform, data marketing-driven solution capabilities and digital precise marketing capabilities based on application scenarios at the pharmacy end.

截至2023年6月30日止六個月，有461家企業級客戶購買本集團的智慧決策雲服務，而2022年上半年有331家客戶，同比增長約39.3%。於2023年上半年，我們智慧決策雲企業級客戶整體復購銷售率為92.2%。

報告期內，我們來自智慧決策雲的收入在報告期內同比增長32.6%，由截至2022年6月30日止六個月的人民幣54.4百萬元增加至截至2023年6月30日止六個月的人民幣72.1百萬元，主要是由於我們數據洞察的業務擴張及SaaS產品得到市場認可帶來的新訂單所產生的收入增加所致。

智慧零售雲

本集團利用超過70,000間合作藥店的獨特優勢，基於在藥店端的應用場景下，建立了「一站式」數據採集平台、數據營銷驅動解決能力和數字精準營銷能力。

MANAGEMENT DISCUSSION AND ANALYSIS 23

管理層討論及分析

Pharmacies using our SIC system can realise operation management, membership management, category management, smart marketing, chronic disease management, pharmaceutical services and other business operations. We are dedicated to assisting pharmacies in enhancing their management efficiency and achieving real-time updates and synchronisation of sales data, thereby reducing operational costs. Through digitisation, we enable seamless communication and facilitate the real-time feedback and collection of retail data from pharmacies. This, in turn, empowers our partnering pharmacies to increase their sales revenue and contributes to the overall growth of our business. Our continuous efforts have resulted in higher member loyalty and consumption willingness at our partnering pharmacies compared to other pharmacies. In addition, we are committed to attracting more pharmaceutical and medical device companies as well as pharmaceutical retailers to join our business expansion plan. Our SaaS product series under the Smart Retail Cloud serve as a valuable tool to enhance the interaction between pharmaceutical and medical device companies and pharmacies and between pharmacies and patients. By doing so, we help patients to develop greater trust in pharmaceutical and medical device products, leading to improved treatment effectiveness, and ultimately, a higher quality of life.

藥店使用我們的SIC系統，可以實現數字化的經營管理、會員管理、品類管理、智能營銷、慢病管理、藥事服務等經營指標。我們能夠幫助藥店提高管理效率，實現銷售數據的實時更新和同步，進一步降低經營成本，同時數字化促進了我們與藥店的實時溝通及藥品零售數據的反饋和收集，從而通過提升我們合作藥店的營業額，為我們的整體業務賦能。通過我們的不懈努力，我們合作藥店的會員忠誠度及消費意願高於其他藥店。此外，我們致力於吸引更多的製藥及醫療設備企業和醫藥零售企業加入我們的業務拓展計劃。我們的智慧零售雲SaaS系列產品可以很好幫助加強製藥及醫療設備企業與藥店之間、藥店與患者之間的深度互動，從而幫助患者提高對藥械產品的信任度，提高治療效果和患者的健康生活水平和生活質量。

24 MANAGEMENT DISCUSSION AND ANALYSIS 管理層討論及分析

We utilise big data processing and analysis to identify potential demands, preferences, and behaviors of retail pharmacies and end-users, and offer pharmaceutical and medical device companies a range of products and professional services including result-oriented and data-driven marketing solutions, precise marketing strategies and professional training services. By doing so, we enable our clients to effectively reach their target audience and quantitatively evaluate the cost-effectiveness of their marketing plans, enhance brand marketing efforts, further control sales expenses, and focus on refined management of cost of sales, ultimately leading to increased market share and marketing revenue.

In addition, we organise industry events such as PHCF and MASC through our industrial ecosystem platform. These events feature comprehensive data analysis, interpretation of policy trends, exploration of new trends in healthcare consumption, and product showcases, aiming to promote the trading of healthcare industry products and facilitate high-quality development of the industry.

For the six months ended 30 June 2023, 443 corporate customers purchased the Group's Smart Retail Cloud services, as compared to 328 corporate customers in the first half of 2022, representing a year-on-year increase of approximately 35.1%. In the first half of 2023, the overall repurchase rate of our Smart Retail Cloud corporate customers was 79.7%.

我們利用大數據處理和分析潛在的零售藥店和終端患者的需求、偏好及行為，向製藥及醫療設備企業提供以效果為導向的數據驅動營銷解決方案、數字精準營銷方案和專業培訓等多種組合產品和專業服務，讓我們的客戶有效地接觸目標受眾，以及量化評估營銷方案的投入產出比，增強產品的品牌營銷力，進一步控制銷售費用支出，同時轉向銷售成本精細化管理，從而提升市場份額和市場營銷收益。

同時，我們亦通過產業生態平台，組織西鼎會、美思會等產業活動通過全景數據分析、解讀政策趨勢、解讀健康消費新趨勢和產品展示等內容，致力於推動健康產業商品交易，促進產業實現高質量發展。

截至2023年6月30日止六個月，有443家企業級客戶購買本集團的智慧零售雲服務，而2022年上半年有328家企業級客戶，同比增長約35.1%。於2023年上半年，我們智慧零售雲企業級客戶整體復購銷售率為79.7%。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

Our revenue from the Smart Retail Cloud services decreased by 5.2% from RMB46.3 million for the six months ended 30 June 2022 to RMB43.8 million for the six months ended 30 June 2023, which was mainly due to the fact that despite our proactive adjustments to individual products with low gross profit margins, our other data-driven and digital precise marketing professional services effectively compensated for and boosted the revenue of this business segment.

SMART MEDICAL CLOUD

This business segment is dedicated to connecting the key participants in the medical value chain, namely hospitals, patients and doctors, in order to build a closed-loop ecosystem, and provide comprehensive patient management solutions for pharmaceutical and medical device companies, medical institutions, and other participants in the medical industry.

The Group has developed a cost-effective approach to integrate the six main functions of medical services, pharmacy services, psychological support, remote intelligent testing, financial assistance and home care based on the life cycle of the patient, and has innovatively provided a whole-process patient care service model by cooperating with pharmaceutical and medical device companies and medical institutions to provide more whole-process management digital therapies + private patient operation solutions. The service model effectively improves the continuity, convenience and autonomy of patients in the treatment process, while also helping pharmaceutical and medical device companies and medical institutions improve their patient management processes.

我們來自智慧零售雲的收入由截至2022年6月30日止六個月的人民幣46.3百萬元減少5.2%至截至2023年6月30日止六個月的人民幣43.8百萬元，主要是由於我們主動對個別低毛利率的產品做出調整所致，但我們的其他數據驅動和數字精準營銷專業服務有效地彌補和提升了該業務分部的收入。

智慧醫療雲

該業務板塊致力於打通醫療價值鏈上的主要參與者：醫院、患者和醫生，共同構建閉環生態，為藥械企業、醫療機構及醫療行業的其他參與者提供患者管理綜合解決方案。

本集團具備低成本高效益的方式，以患者所處的生命週期為基準，將醫療服務、藥事服務、心理支持、遠程智能檢測、經濟援助和居家護理六項主要功能融為一體，與藥械企業和醫療機構共同合作提供更多全病程管理數字療法+私域患者運營方案，創新性地提供了全程患者關護服務模式。這種服務模式有效地提高了患者在治療過程的連續性、便利性和自主性，同時也幫助藥械企業和醫療機構改善患者管理流程。

26 MANAGEMENT DISCUSSION AND ANALYSIS 管理層討論及分析

Meanwhile, the Group fully utilises its resources in medical research, data technology, service talents and ecosystem-based platform to provide innovative pharmaceutical and medical device companies with intelligent solutions such as intelligent medical SaaS, innovative drug research and consulting data, innovative drug marketing and real-world research, and conducts market research in a cost-effective and efficient manner to help pharmaceutical and medical device companies, medical institutions and other participants in the healthcare industry to enhance the efficiency of clinical trials and medical research.

In addition, the Group also leverages its unique strengths accumulated in its AI technology team, medical research team, expert think-tank and medical database to provide medical institutions and doctors with one-stop personalised medical solutions covering more comprehensive clinical decision-making tools and operational services based on professional, scientific and efficient medical knowledge and evidence-based data as well as mature internet-based operational tools to help medical institutions and doctors to solve the problems encountered in the whole treatment process from appointment, consultation, diagnosis, treatment to follow-up, medical record management and analysis, drug and medical device assessment, symptom screening, public health monitoring and public health education in an effective and efficient way, thereby improving the treatment quality.

For the six months ended 30 June 2023, our patient management services have served a total of over 0.2 million patients. In the first half of 2023, the overall repurchase rate of our Smart Medical Cloud customers was 86.5%.

同時，本集團充分利用在醫學研究、數據技術、服務人才、生態平台資源為創新藥械企業提供智慧醫療SaaS、創新藥調研諮詢數據、創新藥營銷、真實世界研究等智能化解決方案，以具備低成本高效益的方式進行市場研究，幫助製藥及醫療設備企業、醫療機構及醫療行業的其他參與者提升臨床試驗及醫學研究的效率。

此外，本集團也利用在AI技術團隊、醫學科研團隊、專家智庫、醫學數據庫積累的獨特優勢，透過專業、科學、高效的醫學知識和循證證據及成熟的互聯網運營工具，為醫療機構和醫生提供更全面的臨床決策工具及運營服務的一站式個性化醫療解決方案，幫助醫療機構和醫生有效且高效的方式解決臨床中遇到的從預約、諮詢、診斷、治療到隨訪、病歷管理與分析、藥物和醫療器械評估、症狀檢測及公共衛生監測到公共衛生教育的整個醫療過程，提升治療水平。

截止2023年6月30日止六個月，我們的患者管理服務，已經累計服務逾20萬患者。於2023年上半年，我們智慧醫療雲客戶整體復購銷售率為86.5%。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

Our revenue from the Smart Medical Cloud services increased by approximately 16.8% from RMB20.0 million for the six months ended 30 June 2022 to RMB23.3 million for the six months ended 30 June 2023, primarily due to the increase in revenue from patient management business.

SMART HEALTH MANAGEMENT CLOUD

In order to promote value-oriented health management and individual health responsibility, we collaborate with medical institutions and health management organisations to provide comprehensive, one-stop artificial intelligence AI-MDT and health management services to physical examination users and patients with various chronic illnesses. With tremendous growth potential, revenue from this business segment recorded year-on-year increase of 799.4% during the Reporting Period.

Our AI-MDT is based on knowledge graphs created using evidence-based medicine and biomedical sciences which, through a deep learning process, can be automatically associated with the corresponding health indicators, symptoms, diagnostic terminologies, treatment or daily care recommendations for various diseases. Users purchasing our AI-MDT can easily obtain efficient and comprehensive health analysis reports. Our AI-MDT can also timely adjust and provide personalised health services and develop reasonable health management plans by automatically managing and tracking users' health indicators through AI-driven automation based on the patients' health status and needs. In addition to health management plans, our AI-MDT can also establish risk prediction models to assist medical institutions and health management organisations in developing personalised strategies and treatment plans for different users. With proper authorisation, we provide medical institutions and health management organisations with relevant insights, knowledge and convenient patient management tools, enabling them to conduct online follow-up and evaluation studies more efficiently. This, in turn, enhances the treatment effectiveness and helps patients lead better lives, thereby empowering us in realising the goal of "Creating Common Interests for the Value of Patients Through Patient-Centered Approaches".

我們來自智慧醫療雲的收入由截至2022年6月30日止六個月的人民幣20.0百萬元增加約16.8%至截至2023年6月30日止六個月的人民幣23.3百萬元，主要得益於患者管理業務的收入增加。

智慧健康管理雲

為了實現價值導向的健康管理及每一個人的健康責任，我們透過醫療機構與健康管理機構，為體檢用戶和不同疾病的慢病人群提供人工智能一站式AI-MDT及配套的健康管理服務。該業務板塊具有巨大增長潛力，報告期間，該板塊的收入同比增長799.4%。

我們的AI-MDT基於以循證醫學和生物醫學為基礎的創建的知識圖譜，並經過深度學習程序，可自動與各種疾病項下相應的健康指標、症狀、診斷術語、治療或日常護理建議等相關聯。用戶購買我們的AI-MDT，可以便捷得到高效及全面的健康分析報告。我們的AI-MDT亦可根據患者的健康狀況和需求，通過人工智能驅動的自動化管理和跟蹤用戶健康指標的變化，及時調整和提供個性化健康服務和制定合理的健康管理計劃。除健康管理計劃外，我們亦能建立風險預測模型，輔助醫療機構及與健康管理機構針對不同用戶的個性化策略及治療計劃。被適當授權後，我們通過向醫療機構及與健康管理機構提供相關洞見和知識以及便利的患者管理工具，令其更高效地進行在線隨訪和評估研究對象，從而提高疾病治療效果，讓患者更好地生活，藉此我們實現以「患者為中心，構建患者價值同心圓」的導向。

28 MANAGEMENT DISCUSSION AND ANALYSIS 管理層討論及分析

Based on user purchasing behavior, we charge medical institutions or health management organisations certain fee for our services. Therefore, we will receive a higher fee for the greater and more frequent demand from users for AI-MDT and the accompanying health management services. During the six months ended 30 June 2023, we have reached over 160 hospitals and 650 private physical examination centers in China. We have over 200,000 paid users who have purchased our services through the hospitals and private physical examination centers at least once. We process a maximum of over 7,300 individual physical examination reports per day, and in the foreseeable future, we plan to expand our services to more medical institutions and health management organisations in more cities in order to serve a larger population of physical examination users.

During the Reporting Period, our revenue from the Smart Health Management Cloud services increased by approximately 799.4% from RMB0.6 million for the six months ended 30 June 2022 to RMB5.7 million for the six months ended 30 June 2023, which was mainly attributable to the increase in revenue from AI-MDT.

FUTURE OUTLOOK

In recent years, there has been a significant increase in the introduction of policies related to data elements, such as the “14th Five-Year Plan for Digital Economy Development”, the “Opinions on Building a Better Data Foundation System to Enhance the Role of Data Elements” and the “Overall Plan for the Construction of Digital China”. Additionally, the establishment of the National Big Data Bureau has played a crucial role. These developments have led to improved systems concerning data element property rights, circulation and transactions, and income distribution. As a result, the data element market has experienced accelerated and standardised growth. This, in turn, has unlocked the untapped potential of data production and application processes, providing a solid foundation and strong impetus for the digitalisation of the healthcare industry.

基於用戶的購買行為，我們會向醫療機構或健康管理機構收取一定的費用。因此，用戶對AI-MDT及配套的健康管理服務的服務需求越大及次數越多，我們收取的費用就越多。截至2023年6月30日止六個月，我們已觸達超過160家醫院、650家民營體檢中心，通過醫院、民營體檢中心購買一次以上的付費用戶超過20萬人，我們最高日處理的個人體檢報告超過7,300份，並且我們擬在可預見未來為更多城市更多醫療機構、健康管理機構提供服務，為更多的體檢人群提供服務。

報告期內，我們來自智慧健康管理雲的收入由截至2022年6月30日止六個月的人民幣0.6百萬元增加約799.4%至截至2023年6月30日止六個月的人民幣5.7百萬元，主要得益於AI-MDT的收入增加。

未來展望

近年來，隨著《「十四五」數字經濟發展規劃》《關於構建數據基礎制度更好發揮數據要素作用的意見》《數字中國整體建設佈局規劃》等數據要素相關政策高頻出台，以及國家大數據局組建成立，數據要素產權制度、流通和交易制度、收益分配制度等更加完善，數據要素市場加速規範化發展，數據生產、數據應用等環節的潛力得到進一步釋放，也為健康產業數字化創造了良好基礎和強大推力。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

The “Healthy China 2030 Planning Outline” has proposed several key measures in response to various factors such as aging population, increasing individuals with suboptimal health, and the rising incidence of chronic diseases like cardiovascular diseases, stroke and type 2 diabetes. These measures are as follows: 1) shifting the focus of healthcare services from a “disease-centered” approach to a “health-centered” approach, providing comprehensive and lifelong services that cater to individuals’ overall well-being; 2) transitioning from a reactive approach of “treating existing diseases” to a proactive approach of “preventing diseases”, placing greater emphasis on health education, disease prevention and health promotion; and 3) shifting the responsibility for healthcare from solely relying on the healthcare system to promoting a holistic societal approach, which involves fully mobilising individuals, families and other stakeholders. This marks the beginning of a new era in China’s healthcare industry, where individuals are encouraged to take personal ownership of their health and actively involve in making decisions about their own well-being as the primary custodians of their personal health. Through digitisation and empowering individuals with access to information and resources, various aspects of the healthcare industry chain, such as pharmacies, hospitals, smart devices, physical examinations and food industry, are interconnected to meet the diverse and evolving health needs of individuals. At the same time, a healthcare system centered around individual health requires massive data and tool support, leading to an explosive growth of big data and digital products in healthcare industry.

隨著人口老齡化、居民消費升級、亞健康人群增加和慢性病(心血管疾病、中風、II型糖尿病等)發病率提高等多因素影響，《健康中國2030規劃綱要》提出：1)醫療衛生服務從以「疾病」為中心向以「健康」為中心轉變，提供全方位全週期健康服務，2)從「治已病」向「治未病」轉變，注重健康教育、疾病預防和健康促進，3)從依靠衛生健康系統向社會整體聯動轉變，充分調動個人、家庭等力量。至此，中國健康產業進入了「個人健康主體責任新時代」，強調個人主動參與健康決策，是自己健康的第一責任人，通過數字化「賦能」，將個人健康需求連接到藥店、醫院、智能設備、體檢、食品等不同產業鏈的資源，滿足多樣化的健康需求。同時，以個人健康為中心的醫療健康體系，需要海量數據和工具支持，健康大數據和數字化產品將迎來爆發式增長。

30 MANAGEMENT DISCUSSION AND ANALYSIS 管理層討論及分析

Standing at the forefront of the wave of digital transformation of healthcare industry participants empowered by the application of big data technology, artificial intelligence and cloud computing, the Group will uphold the corporate mission of “developing smart healthcare industry and promoting smart healthy life”, and focus on helping participants of the healthcare industry establish the core capabilities of efficient decision-making and precise connection through the means of technological innovation, so as to enhance marketing effectiveness and research and development efficiency. The Group will focus on the supply of high-quality data elements, and place greater emphasis on in data labeling, data cleansing, desensitisation, decryption, aggregation, analysis and other processes in order to improve its data resources processing capabilities. It will also promote the construction of standard systems of data resources in the healthcare industry, improve data management levels and data quality, and is committed to helping customers deeply integrate digital application technologies. The Group will also promote digital transformation in the development and design, operation management and marketing of enterprises in the healthcare industry, in order to help the industry speed up the remedy for the shortcomings of digital transformation and empower the industry to transform and upgrade, thus creating an industrial structure of high-quality development.

本集團站在應用大數據技術、人工智能、雲計算賦能健康產業參與者數字化轉型浪潮的前沿，將秉持「智慧健康產業，智慧健康生活」的企業使命，通過科技創新手段，專注於幫助健康產業參與者建立高效決策和精準連接兩種核心能力，提高營銷效率和研發效率。本集團將聚焦於高質量數據要素供給，發力數據的標注、清洗、脫敏、脫密、聚合、分析等環節，提升數據資源處理能力；推動健康產業數據資源標準體系建設，提升數據管理水平和數據質量，致力於幫助客戶深度融合數字應用技術，推動在研發設計、經營管理、市場營銷等方面的數字化轉型，幫助產業加快補齊數字化轉型短板弱項，賦能產業轉型升級，打造高質量發展的產業格局。

Maximising the value of data element. Data element is the core engine for the in-depth development of the digital economy. It is not only increasingly important in multiplying the production efficiency of the healthcare industry prominent, but also is the core asset on which the Group relies for its development. In order to further consolidate our leading position in the industry and play a leading role in the development of data elements, we will 1) expand the depth and breadth of data collection, consolidate the core value of data and connect more pharmaceutical and medical device retail markets, medical institutions and physical examination centers to enhance our data scale; 2) strengthen data governance, artificial intelligence and cloud computing capabilities, maintain our industry-leading data governance capabilities, create structured and standardised data benchmarks, enhance the applicability and authority of data, and continuously enrich and deepen insights into the market as well as the understanding and application of various disease areas; 3) adhere to market orientation and continuously realise the iteration and optimisation of products and services to meet the high-quality development needs of the industry; 4) use industrial data to empower the industrial ecology and fully utilise the function of connection to establish an efficient communication and cooperation platform for the industry participants, meanwhile using the platform to efficiently connect with customers to improve the conversion rate and penetration rate of our various businesses; and 5) further expand our database, create a new and extensive product matrix and open up new market segments through strategic cooperation, project investment and equity mergers and acquisitions.

發揮數據要素最大價值。數據要素是數字經濟深化發展的核心引擎，對提高健康產業生產效率的乘數作用不斷凸顯，也是本集團賴以發展的核心資產。為進一步鞏固我們的行業領先地位，發揮數據要素的發展引領作用，我們將1)擴大數據採集的深度和廣度，夯實核心數據價值，連接更多的藥械零售市場、醫療機構和體檢中心，提升數據規模；2)加強數據治理、人工智能和雲計算能力，保持行業領先的數據治理能力，打造結構化和標準化的數據標桿，提升數據的適用性和權威性，並不斷豐富和深化對市場的洞察能力以及各疾病領域的認識和應用；3)堅持市場導向，持續實現產品和服務的迭代和優化，滿足行業高質量發展需求；4)利用產業數據賦能產業生態，充分發揮連接作用，為產業參與者打造高效的溝通和合作平台，同時利用平台高效連接客戶，提高我們各項業務的轉化率和滲透率；及5)通過戰略合作、項目投資和股權併購等方式，進一步擴容數據庫，打造新豐富產品矩陣，開拓新細分市場。

32 MANAGEMENT DISCUSSION AND ANALYSIS 管理層討論及分析

Expanding the advantage of market leadership. For market strategy, the Group will continue its initiatives to develop key customers and key markets, provide key customers with customised products and services that better meet their needs, strengthen the relationship with customers, increase the number of products per customer, and achieve simultaneous growth in number of industry-leading customers and unit price of customer. Meanwhile, we will develop the long tail market relying chiefly on our standard products, so as to facilitate rapid development of our business scale in an all-round way. In addition, we will follow up the needs of new customer groups such as securities dealers, funds and business research institutions, provide customised SaaS products and business insight reports, continuously expand new customer groups, and enhance the influence of the Group's data products on the industry and its benchmarking attributes, with a view to establishing its market leadership in multiple dimensions.

OUTLOOK ON MAIN BUSINESSES

In order to maximise the efficiency of resource allocation, optimise its strategic development layout and achieve high-quality sustainable development, the Group has formulated "short, medium and long-term" business development plans. We will continue to expand our leading edge in Smart Retail Cloud and Smart Decision Cloud segments to gain a larger market share, and will continue to optimise the products under Smart Medical Cloud and Smart Health Management Cloud, accelerate market expansion, expand its business scale, thus forming new drivers for its profit growth. The Group plans to build a closed-loop database of "patients, pharmacies, hospitals, physical examinations, pharmaceutical and medical device production and insurance", so as to establish the advantage of large-scale and standardised data covering the whole industry, thereby maximising the value of data element.

擴大市場領先優勢。在市場戰略方面，本集團將持續開拓關鍵客戶和重點市場的舉措，為關鍵客戶提供更符合其需求的定制化產品和服務，鞏固雙方合作關係，提升客均產品數，實現產業頭部客戶數量和客單價同時保持增長；同時，我們將以標準產品為主開拓長尾市場，全方位推動業務規模的快速發展。另外，我們也關注到券商、基金、商業研究機構等新客戶群體的需求，為其提供定制化SaaS產品以及商業洞察報告，不斷擴大新客戶群體，提升本集團數據產品的行業影響力和標桿屬性，多維度打造市場領先地位。

主營業務展望

為最大化發揮資源配置效能，優化戰略發展佈局，實現高質量可持續發展，本集團已經制定「短、中、長」三個時間維度的業務發展規劃。我們將持續擴大在智慧零售雲和智慧決策雲的領先優勢，獲取更大的市場份額；繼續優化智慧醫療雲和智慧健康管理雲的產品，加速搶佔市場，擴大業務規模，形成新的盈利增長點；本集團計劃在未來構建起「患者、藥店、醫院、體檢、藥械生產、保險」閉環數據庫，建立起覆蓋全產業、規模領先、標準通用的數據優勢，實現數據要素價值最大化。

1) Smart Decision Cloud. Combining industry trends, customer needs and its own operating experience, the Group will continue to optimise existing products and develop new products to achieve more efficient ecological links in order to meet the diverse needs of pharmaceutical manufacturers and other customers. The Group will continue to enhance its competitive advantages in multiple dimensions such as data scale, industrial ecology, market insight, decision support and industry foresight, create differentiated product competitiveness, and help customers reduce costs and enhance efficiency. Meanwhile, the Group will be committed to creating data standards for the healthcare industry, improving the influence of the industry and enabling Sinohealth's data to contribute to the high-quality development of the industry. The Group will optimise the innovative contents of the conference by improving the forward-looking insight of the healthcare industry in a data-driven approach, with a view to establishing an international healthcare industry conference system. The Group is actively preparing for a traditional Chinese medicine conference and is also developing data products that focus on traditional Chinese medicine conference to accelerate the expansion of the traditional Chinese medicine market and contribute to the high-quality development of traditional Chinese medicine industry by leveraging the power of data.

1) 智慧決策雲。結合行業趨勢、客戶需求和自身運營經驗，本集團將持續優化已有產品和開發新產品，實現更高效的生態鏈接，以滿足醫療企業生產商和其他客戶的多元需求。本集團將持續提升在數據規模、產業生態、市場洞察、決策支持、產業前瞻等多個維度的競爭優勢，打造差異化的產品競爭力，助力客戶實現降本增效。同時，本集團將致力於打造健康產業的數據標準，提高產業話語權，讓中康數據更好地助力產業高質量發展。利用數據賦能提升健康產業前瞻洞察力，優化創新會議內容，打造國際化的健康產業會議體系。本集團正在籌備中醫藥大會和開發中醫藥數據產品，加快開拓中醫藥市場，為中醫藥的高質量發展貢獻數據力量。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

2) Smart Retail Cloud. We will further improve and expand the capabilities of SIC to empower pharmacies in areas such as membership management, chronic disease care and management, professional training, drug purchase guidance, and supply chain management. This will help pharmacies establish themselves as a “gateway to health management”, offering customers more professional, efficient and comprehensive health management services. By increasing the connection between pharmacies and personal health, we aim to help pharmacies improve their quality and efficiency. In addition, the extensive use of SIC will help the Group strengthen its partnerships with various pharmaceutical retailers, expand the coverage of pharmacy data, and maintain the Group’s leading position in terms of data scale, granularity, coverage, timeliness and other aspects.

3) Smart Medical Cloud. We will continue to expand our business layout, enhance our data scale and explore more commercial models. The Group has been operating in the medical sector for many years, and has established and operated a medical data processing platform, a full-range care service system for patients, multiple tumor MDT academic platforms and full-course management and evaluation systems for hospitals. We will integrate existing resources and, focusing on the goal of “serving as an accelerator for the commercialisation of innovative pharmaceutical and medical devices”, help innovative pharmaceutical and medical device companies to effectively connect patients, doctors and experts in the aspects of program design, intelligent systems and operational services. Based on the core competence of Sinohealth-Engine and the network of hospitals and experts accumulated in the big data platform and the solution sector, and focusing on the full life-cycle of pharmaceutical and medical devices from clinical development to post-launch marketing, we provide enterprises with personalised digital products, including products for intellectual property scientific research collaboration, artificial intelligence and medical inter-disciplinary research and the research and development of AI technology-based patient management products, thereby rapidly achieving the best commercialisation solutions.

2) 智慧零售雲。我們將進一步優化和增加SIC的功能，賦能藥店推進會員管理、慢病關懷和管理、專業培訓、藥品導購、供應鏈管理等方面能力建設，助力藥店打造「健康管理入口」，為客戶提供更專業、更高效、更全面的健康管理服務，提高藥店和個人健康的關聯度，從而助力藥店實現提質增效。同時，SIC的廣泛使用將保障本集團得以加強與各醫藥零售企業的合作關係，提升藥店數據覆蓋廣度，確保本集團保持在數據規模、顆粒度、覆蓋範圍、及時性等方面的領先地位。

3) 智慧醫療雲。我們將持續擴大業務佈局、提升數據規模、以及探索更多商業化模式。本集團在醫療領域耕耘多年，搭建並運營著醫療數據治理平台、全程患者關護服務體系、多個腫瘤MDT學術平台、醫院全病程管理及評價系統等。我們將整合現有資源，聚焦「創新藥械商業化的加速器」這一目標，幫助創新藥械公司，在方案設計、智能系統、運營服務三個方面，實現有效聯結患者、醫生、專家，基於Sinohealth-Engine的核心能力以及在大數據平台和解決方案板塊積累的醫院和專家網絡，圍繞藥物和醫療器械從臨床開發到上市後營銷的全生命週期，為企業提供包括IP科研協作、人工智能+醫學交叉研究協同創新、基於AI技術的患者管理產品研發等產品在內的個性化數字產品，迅速找到商業化最佳實踐方案。

4) Smart Health Management Cloud. According to publicly available statistics, the number of physical examinations in China has exceeded 500 million per year. With the improvement of national health awareness, the number of physical examinations and the demand for health management will continue to grow, which will create a larger market space for AI-MDT and supporting health management services. We will continue to utilise our advantages in data, knowledge and expert network to provide more in-depth and effective AI-MDT physical examination reports for the physical examination population. We will also further optimise and expand product functions, and collaborate more with hospitals and physical examination institutions to provide services such as physical examination data management, health profiling, post-examination product packages, post-examination services, chronic disease management and marketing tools, so as to meet the needs for post-examination health management of multi-level population, help physical examination centers develop the market and build diversified customer acquisition channels, so that more people can access AI-MDT to enjoy better health management services.

5) Smart Clinic Cloud. The “Opinions on Further Deepening Reform and Promoting the Healthy Development of the Rural Medical and Health System” issued by the State Council of China proposes to support the construction of county-level hospital facilities and service capabilities, in order to achieve significant improvement in infrastructure conditions and gradually popularise intelligent and digital applications for the prevention and treatment of diseases and the significant improvement in health management capabilities. With the support of this policy, county level outpatient clinics will accelerate their digital transformation and our Woodpecker outpatient clinics may experience larger room for growth.

4) 智慧健康管理雲。根據公開研究數據，我國體檢人群已經突破5億人次／年，伴隨國民健康意識提高，體檢人數和健康管理需求將保持增長，這也為AI-MDT以及配套的健康管理服務創造了更大的市場空間。我們將繼續利用數據、知識及專家網絡等方面的優勢，為體檢人群提供更深度、更有效的AI-MDT體檢報告。我們還將進一步優化和擴展產品功能，與醫院和體檢機構達成更多合作內容，比如提供體檢數據治理、健康畫像、檢後產品服務包、檢後服務、慢病管理和營銷工具等，以滿足多層次人群的檢後健康管理需求，助力體檢中心拓展市場和搭建多元化獲客渠道，讓更廣闊人群使用AI-MDT，享受更好的健康管理服務。

5) 智慧診所雲。中國國務院《關於進一步深化改革促進鄉村醫療衛生體系健康發展的意見》提出支持縣級醫院設施和服務能力建設，達到基礎設施條件明顯改善，智能化、數字化應用逐步普及，防病治病和健康管理能力顯著提升的效果。在此政策支持下，縣域門診將加快數字化轉型，卓睦烏門診或將迎來較大的增長空間。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

6) Smart Insurance Cloud. With the continuous expansion of smart health management, smart medical care, smart clinics and other businesses, it is expected that the scale of the Group's medical data, physical examination data and innovative pharmaceutical and medical device data will achieve a rapid growth, thus forming a closed-loop healthcare industry database together with the already leading retail market data, so that the effects of scale and network can be fully leveraged. As such, the Group is enabled to develop products and services that can meet the needs of big data intelligent application for commercial insurance, and provide commercial insurance institutions with professional SaaS products and supporting professional services at various aspects such as product design, sales channels, customer profile and business strategies, thus finally achieving a closed-loop in the Group's business of full life-cycle health management at the insurance service sector.

Under the long-term trend of the dualisation of the healthcare industry and the rapid development of the digital industry, the Group has ushered in an unprecedented opportunity to achieve a leapfrog development. We will continue to explore and practice in the field of healthcare industry services, improve product quality and professional service capabilities, and provide customers with multi-level and diversified digital applications and solutions. We are aiming to establish industry benchmarks and leading capabilities so as to actively promote high-quality development of the healthcare industry.

6) 智慧保險雲。隨著智慧健康管理、智慧醫療、智慧診所等業務的持續拓展，預計本集團的醫療數據、體檢數據、創新藥械數據的規模將實現快速增長，與已具備領先地位的零售市場數據形成健康產業數據閉環，發揮出更大的規模效應和網絡效應，保障本集團開發出可以滿足商業保險大數據智能應用需求的產品和服務，為商業保險機構在產品設計、銷售渠道、客戶畫像、經營策略、市場管理等方面提供專業SaaS產品以及配套專業服務，最終在保險服務終端完成本集團在全生命週期健康管理的業務閉環。

在健康產業二元化和數字產業快速發展的長期趨勢下，本集團迎來了實現跨越式發展的歷史機遇，我們將不斷在健康產業服務領域探索和實踐，提升產品質量和專業服務能力，為客戶提供多層次、多樣化的數字化應用和解決方案，打造行業標桿和引領能力，積極推動健康產業的高質量發展。

FINANCIAL REVIEW

Revenue

In the first half of 2023, the Group generated revenue from four business segments, namely Smart Decision Cloud; Smart Retail Cloud; Smart Medical Cloud; and Smart Health Management Cloud. The Group's revenue increased by approximately 19.6% from approximately RMB121.2 million for the six months ended 30 June 2022 to approximately RMB145.0 million for the six months ended 30 June 2023, which was mainly due to the increase in revenue from the Smart Decision Cloud.

Cost of Sales

The Group's cost of sales primarily consisted of (i) staff costs related to our employee benefits for our employees in relation to the daily operation and maintenance of our solutions and products; and (ii) event costs mainly relating to venue and equipment rentals, event planning and organisation services fees, accommodation and catering costs. The Group's cost of sales increased by approximately 8.1% from approximately RMB64.6 million for the six months ended 30 June 2022 to approximately RMB69.8 million for the six months ended 30 June 2023, which was mainly due to the increase in cost of sales driven by the growth of the Group's business.

Gross Profit and Gross Profit Margin

The Group's gross profit for the six months ended 30 June 2023 amounted to approximately RMB75.2 million, representing an increase of approximately 32.7% as compared to RMB56.7 million for the first half of 2022. The Group's gross profit margin increased by 5.2 percentage points from approximately 46.7% for the six months ended 30 June 2022 to approximately 51.9% for the corresponding period of 2023.

財務回顧

收益

2023年上半年，本集團的收益來自四類業務，即智慧決策雲；智慧零售雲；智慧醫療雲；及智慧健康管理雲。本集團的收益由截至2022年6月30日止六個月約人民幣121.2百萬元增加約19.6%至截至2023年6月31日約人民幣145.0百萬元，主要是由於智慧決策雲的收益增加。

銷售成本

本集團的銷售成本主要包括(i)與我們的解決方案及產品的日常運營及維護有關的且與我們的員工福利相關之員工成本；及(ii)主要與租用場地及設備、活動策劃及組織服務費、住宿及餐飲成本有關的活動成本。本集團的銷售成本由截至2022年6月30日止六個月約人民幣64.6百萬元增加約8.1%至截至2023年6月30日止六個月約人民幣69.8百萬元，主要是由於本集團業務增長帶動銷售成本增加所致。

毛利及毛利率

本集團截至2023年6月30日止六個月的毛利約為人民幣75.2百萬元，較2022年上半年的人民幣56.7百萬元增加約32.7%。本集團的毛利率由截至2022年6月30日止六個月的約46.7%增加5.2個百分點至2023年同期的約51.9%。

38 MANAGEMENT DISCUSSION AND ANALYSIS 管理層討論及分析

Other Income and Gains

Other income and gains primarily consisted of (i) government grants; (ii) foreign exchange gains; and (iii) bank interest income. The Group recorded other income and gains of approximately RMB35.8 million for the six months ended 30 June 2023, representing an increase of approximately 229.8% as compared to approximately RMB10.9 million for the six months ended 30 June 2022. Such increase was mainly due to (i) the increase in foreign exchange gains and (ii) the increase in interest income, especially due to the proceeds from the Global Offering.

Selling and Distribution Expenses

Selling and distribution expenses mainly consist of (i) employee benefit expenses for employees responsible for sales and marketing functions; (ii) travel and transportation expenses related to offline marketing campaigns, the development and maintenance of customer relationship and production of advertising materials; and (iii) general office expenses. For the six months ended 30 June 2023, the Group's selling and distribution expenses amounted to approximately RMB15.1 million, which generally remained the same as compared to approximately RMB15.1 million for the six months ended 30 June 2022.

Administrative Expenses

The Group's administrative expenses primarily consisted of (i) employee benefits expenses; and (ii) professional fees. The Group's administrative expenses decreased by approximately 19.2% from approximately RMB18.7 million for the six months ended 30 June 2022 to approximately RMB15.1 million for the six months ended 30 June 2023, which was mainly due to the decrease in the listing expenses.

其他收入及收益

其他收入及收益主要包括(i)政府補助；(ii)匯兌收益；及(iii)銀行利息收入。本集團截至2023年6月30日止六個月錄得其他收入及收益約人民幣35.8百萬元，較截至2022年6月30日止六個月約人民幣10.9百萬元增加約229.8%。增加主要是由於(i)匯兌收益增加及(ii)利息收入增加，尤其是因全球發售所得款項所致。

銷售及分銷開支

銷售及分銷開支主要包括(i)負責銷售和營銷職能的員工的僱員福利開支；(ii)與線下營銷活動和客戶關係發展與維護及廣告素材製作相關的差旅及交通開支；及(iii)一般辦公開支。截至2023年6月30日止六個月，本集團的銷售及分銷開支約人民幣15.1百萬元，整體與2022年6月30日止六個月的約人民幣15.1百萬元比較，保持持平。

行政開支

本集團的行政開支主要包括(i)僱員福利開支；及(ii)專業費用。本集團的行政開支由截至2022年6月30日止六個月約人民幣18.7百萬元減少約19.2%至截至2023年6月30日止六個月約人民幣15.1百萬元，主要由於上市開支減少所致。

Research and Development Costs

The Group's research and development costs primarily consisted of (i) employee benefits expenses; (ii) depreciation of right-of-use assets and (iii) technology services fees and general office expenses. The Group's research and development costs decreased by approximately 4.5% from approximately RMB28.5 million for the six months ended 30 June 2022 to approximately RMB27.2 million for the six months ended 30 June 2023, primarily due to a decrease in employee benefits expenses.

Profit before Tax

Based on the above reasons, the Group's profit before tax increased by approximately 1,119.9% from approximately RMB3.9 million for the six months ended 30 June 2022 to approximately RMB47.9 million for the six months ended 30 June 2023.

Income Tax Expense

The Group's income tax expense amounted to approximately RMB0.9 million for the six months ended 30 June 2023, as compared to income tax credit of approximately RMB1.4 million for the six months ended 30 June 2022, representing an increase of approximately 167.7% in income tax expense, which was mainly due to the increase in profit before tax.

Profit for the Period

As a result of the foregoing, the Group's profit for the period increased by approximately 788.4% from approximately RMB5.3 million for the six months ended 30 June 2022 to approximately RMB47.0 million for the six months ended 30 June 2023.

研究及開發成本

本集團的研究及開發成本主要包括(i)僱員福利開支；(ii)使用權資產折舊及(iii)技術服務費用及一般辦公室開支。本集團的研究及開發成本由截至2022年6月30日止六個月約人民幣28.5百萬元下降約4.5%至截至2023年6月30日止六個月約人民幣27.2百萬元，主要由於僱員福利開支減少所致。

除稅前溢利

基於上述理由，本集團的除稅前溢利由截至2022年6月30日止六個月約人民幣3.9百萬元增加約1,119.9%至截至2023年6月30日止六個月約人民幣47.9百萬元。

所得稅開支

本集團截至2023年6月30日止六個月的所得稅開支為人民幣0.9百萬元，對比截至2022年6月30日止六個月的所得稅抵免約為人民幣1.4百萬元，所得稅開支增加約167.7%，主要由於除稅前溢利增加。

期內溢利

由於以上所述，本集團期內溢利由截至2022年6月30日止六個月約人民幣5.3百萬元增加約788.4%至截至2023年6月30日止六個月約人民幣47.0百萬元。

40 MANAGEMENT DISCUSSION AND ANALYSIS 管理層討論及分析

Liquidity and Capital Resources

For the six months ended 30 June 2023, the Group financed its operations mainly through cash generated from the Group's operating activities. The Group intends to continue to finance its expansion and business operations using a combination of cash generated from operating activities and the net proceeds from the Global Offering.

Cash and Cash Equivalents

The Group maintains a strong cash position. For the six months ended 30 June 2023, the Group's total cash and cash equivalents amounted to approximately RMB199.2 million, representing a decrease of approximately 51.3% from RMB409.3 million as at 31 December 2022. Such decrease was mainly due to the fact that the Company deposited certain funds in licensed financial institutions as fixed deposits. As at 30 June 2023, the Group's cash and cash equivalents were mainly denominated in RMB.

Borrowings

During the six months ended 30 June 2023, the Group did not have any short-term or long-term bank borrowings and had no outstanding bank and other borrowings and other indebtedness apart from lease liabilities for the relevant lease terms amounting to approximately RMB16.7 million in aggregate.

Gearing Ratio

The gearing ratio, which is calculated by dividing total liabilities by total equity, was 18.2% as at 30 June 2023 (31 December 2022: approximately 14.9%).

流動資金及資本資源

截至2023年6月30日止六個月，本集團主要通過本集團經營活動所得現金。本集團擬繼續利用經營活動所得現金和全球發售所得款項淨額為擴張及業務運營提供資金。

現金及現金等價物

本集團維持強勁現金狀況。截至2023年6月30日止六個月，本集團的現金及現金等價物總值約人民幣199.2百萬元，較2022年12月31日的人民幣409.3百萬元減少約51.3%，主要是由於本集團將部分資金存入持牌金融機構作定期存款，於2023年6月30日，本集團的現金及現金等價物主要以人民幣計值。

借款

截至2023年6月30日止六個月，本集團並無任何短期或長期銀行借款，除總計約人民幣16.7百萬元的相關租賃條款的租賃負債外，亦無未償還銀行及其他借款及其他債務。

資產負債比率

截至2023年6月30日，資產負債比率(按總負債除以權益總額計算)為18.2%(2022年12月31日：約14.9%)。

Foreign Currency Risk

The Group has transactional currency exposures and are subject to foreign currency risk arising from fluctuations in exchange rates between RMB and US\$. As at 30 June 2023, the Group had transactional currency exposures. Such exposures arose from its cash and cash equivalents and fixed deposits in US\$. The Group is currently not engaged in hedging activities that are designed or intended to manage foreign exchange rate risk. The Group will continue to monitor foreign exchange activities and make its best efforts to protect the cash value of the Group.

Charge on Assets

As at 30 June 2023, the Group did not pledge any of its assets.

Cash Flow and Capital Expenditure

As at 30 June 2023, the Group's capital expenditures were mainly incurred for the acquisition of equipment and software, which remained at a limited level of approximately RMB1.7 million, representing an increase of approximately 32.4% as compared to the six months ended 30 June 2022.

The Group intends to fund future capital expenditures from cash balance, cash generated from operating activities and proceeds from the Global Offering. The Group will continue to incur capital expenditures to meet the expected growth of the business, and may reallocate funds for capital expenditures and long-term investments based on the Group's ongoing business needs.

Contingent Liabilities and Guarantees

As at 30 June 2023, the Group did not have any significant contingent liabilities, guarantees or any material litigation against the Group.

外匯風險

本集團面臨交易貨幣風險，並面臨著因人民幣與美元之間的匯率波動而產生的外幣風險。截至2023年6月30日，本集團存在交易貨幣風險。有關風險來自以美元計值的現金及現金等價物及定期存款。本集團現時未有從事旨在或意在管理外匯匯率風險的對沖活動。本集團將繼續監察外匯活動，並盡最大努力保障本集團的現金價值。

資產抵押

截至2023年6月30日，本集團並無抵押任何資產。

現金流量及資本開支

截至2023年6月30日，本集團資本開支主要就設備和軟件收購所產生，仍保持於約人民幣1.7百萬元的有限水平，較截至2022年6月30日止六個月增加約32.4%。

本集團擬以現有銀行結餘、經營活動所得的現金及全球發售的所得款項撥付未來資本開支。本集團將繼續產生資本開支，以滿足業務的預期增長，並可能根據本集團持續的業務需要將資金重新分配以用於資本開支及長期投資。

或然負債及擔保

截至2023年6月30日，本集團並無任何重大的或然負債、擔保或針對本集團的任何重大訴訟。

42 MANAGEMENT DISCUSSION AND ANALYSIS 管理層討論及分析

Significant Acquisitions or Disposals and Future Plans for Significant Investments

The Group did not have any significant acquisitions or disposals of subsidiaries, associates and joint ventures as at 30 June 2023.

As at 30 June 2023, none of each individual investment held by the Group constituted 5% or more of the total assets of the Group, and there is no future plan for any material investment or capital assets.

Employees and Staff Costs

As at 30 June 2023, the Group had a total of 698 (30 June 2022: 673) full time employees, all of whom were located in Mainland China. For the six months ended 30 June 2023, the Group recognised staff costs of approximately RMB66.6 million, representing a decrease of approximately 7.8% as compared to the six months ended 30 June 2022.

The increase in the number of employees of the Group in the first half of 2023 was primarily due to the Group's expansion of the solutions and products team and sales team in response to the Group's business needs. As at 30 June 2023, 124, 90 and 154 of the Group's employees possessed medical expertise, medicine expertise and computer science expertise, respectively. The Group's specialised talents have more than seven years' industrial experience on average.

重大收購或出售及主要投資未來計劃

截至2023年6月30日，本集團並無就附屬公司、聯營企業及合營企業進行任何重大收購或出售事項。

截至2023年6月30日，本集團持有的每項投資均不構成本集團總資產的5%或以上，且未來亦無重大投資或資本資產計劃。

僱員及員工成本

於2023年6月30日，本集團共有698名全職僱員(2022年6月30日：673名)，全部均位於中國內地。截至2023年6月30日止六個月，本集團確認員工成本約人民幣66.6百萬元，較截至2022年6月30日止六個月減少約7.8%。

本集團於2023年上半年的員工數目增加，主要由於本集團為應對業務需要而擴大解決方案及產品團隊以及銷售團隊所致。截至2023年6月30日，本集團的員工中分別有124名擁有醫學專業知識、90名擁有醫藥專業知識及154名擁有計算機科學專業知識。本集團的專業人才平均擁有逾七年的行業經驗。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

The following table sets forth the number of employees by function, and the percentage of each function to the Group's total number of employees as at 30 June 2023.

下表載列截至2023年6月30日按職能分類的員工人數，以及各類員工佔員工總數的百分比。

Function	職能	Number	Percentage to the total number of employees 佔總人數的百分比
Solutions, Products and Services	解決方案·產品及服務	275	39.4%
Research and Development	研發	241	34.5%
Sales and Marketing	銷售及營銷	117	16.8%
General and Administrative	總務及行政	65	9.3%
Total	合計	698	100%

The Group embraces diversity and focuses on equal opportunity during its recruitment process. The Group also highly values employees and places an emphasis on the development of employees. In order to advance the skills and knowledge of employees as well as to explore new potential from within the Group's workforce, the Group invests in continuing education and training programs for the management and other staff members to update their skills and knowledge periodically. Generally, the Group's training focuses on operations, technical knowledge, intellectual property protection and work safety standards. The Group has also established various internal professional committees working on a variety of areas such as pharmacy and medicine, data and technology, and industry development, to promote employees' professional development and encourage exchange of information.

在招聘過程中，本集團主張多元性，並重視平等機會。本集團亦高度重視員工及員工發展。為了提升員工的技能和知識，發掘員工的新潛力，本集團為管理層和其他員工提供繼續教育和培訓項目，以定期更新他們的技能和知識。一般來說，本集團的培訓主要注重與本集團的運營、技術知識、知識產權保護和工作安全標準相關的事項。本集團亦建立以藥學和醫學、數據和技術、行業發展等為主題的多個內部專業委員會，以促進員工的專業發展和鼓勵信息交流。

44 MANAGEMENT DISCUSSION AND ANALYSIS 管理層討論及分析

The remuneration package of the Group's employees includes basic salary, performance bonuses and allowances. The Group determines employee remuneration based on factors such as competency, performance, qualifications, expertise and years of experience. The Group typically enters into employment contracts and confidentiality agreements with its employees.

The Group participates in and makes contributions to housing funds and social insurance contribution plans organised by the relevant local municipal and provincial governments, including pension, medical insurance, unemployment insurance, work-related injury insurance, maternity insurance, and housing fund plans.

In addition, to provide incentive or reward to eligible persons for their contribution to, and continuing efforts to promote the interests of the Group, the Company has adopted the Share Option Scheme and the Share Award Scheme.

Subsequent Events

No significant events that require additional disclosure or adjustments occurred after the end of the Reporting Period and up to the date of this report.

本集團員工的薪酬待遇包括基本工資、績效獎金和津貼。本集團根據能力、表現、資歷、專業知識和工作經驗等因素釐定員工薪酬。本集團通常與員工簽訂僱傭合約和保密協議。

本集團參加並繳納當地省及市政府組織的住房公積金及社會保險供款計劃，包括養老保險、醫療保險、失業保險、工傷保險、生育保險、以及住房公積金計劃。

此外，為了激勵或獎勵對本集團作出貢獻及持續努力促進本集團利益的合資格人士，本公司已採納購股權計劃和股份獎勵計劃。

期後事項

本集團自報告期結束後至本報告日期並無發生須進一步披露或調整的重大事項。

CORPORATE GOVERNANCE AND OTHER INFORMATION

企業管治及其他資料

COMPLIANCE WITH CORPORATE GOVERNANCE CODE 遵守企業管治守則

The Company is committed to maintenance of good corporate governance practices and procedures. The principle of the Company's corporate governance is to promote effective internal control measures, uphold a high standard of ethics, transparency, responsibility and integrity in all aspects of business, to ensure that its business and operations are conducted in accordance with applicable laws and regulations and to enhance the transparency and accountability of the Board to all Shareholders. The Company's corporate governance practices are based on the principles and code provisions as set out in part 2 of the CG Code.

Pursuant to code provision C.2.1 of the CG Code, companies listed on the Stock Exchange are expected to comply with, but may choose to deviate from the requirement that the responsibilities between the chairman and the chief executive officer should be segregated and should not be performed by the same individual. The Company does not have a separate chairman and chief executive officer and Mr. Wu Yushu currently performs these two roles concurrently. The Board believes that vesting the roles of both the chairman and chief executive officer in the same person has the benefit of ensuring consistent leadership within the Group for more effective and efficient overall strategic planning for the Group. The Board considers that the balance of power and authority within the Group will not be impaired by the present arrangement and the current structure will enable the Company to make and implement decisions more promptly and effectively. The Board will from time to time review and consider splitting the roles of chairman of the Board and the chief executive officer of the Company to ensure appropriate and timely arrangements are in place to meet changing circumstances.

Save for the deviation from code provision C.2.1 of the CG Code as described above, the Company had complied with all applicable code provisions set out in part 2 of the CG Code during the Reporting Period.

本公司致力於維持良好的企業管治常規及程序。本公司企業管治原則旨在推行有效的內部控制措施，在業務的各個方面均堅持高標準的道德、透明度、責任感及誠信度，以確保其業務及營運均按照適用法律法規進行，並提高董事會對全體股東的透明度及問責制。本公司的企業管治常規以企業管治守則第二部分所載原則及守則條文為基礎。

根據企業管治守則的守則條文第C.2.1條，聯交所上市公司應遵守主席與首席執行官的職責應有區分，並不應由一人同時兼任的規定，但亦可選擇偏離該規定行事。本公司並無區分主席與首席執行官，吳鬱抒先生目前兼任該兩個職位。董事會相信，由同一人兼任主席與首席執行官的角色，可確保本集團內部領導貫徹一致，使本集團的整體策略規劃更有效及更具效率。董事會認為，現行安排將不會損害本集團權力與權限之間的平衡，而現行架構將使本公司能夠更迅速及有效地作出及實施決策。董事會將不時檢討及考慮將董事會主席與本公司首席執行官的角色分開，以確保作出適當而及時的安排，從而應對不斷變動的情況。

除上述偏離企業管治守則的守則條文第C.2.1條的情況外，本公司於報告期間一直遵守企業管治守則第二部分所載的所有適用守則條文。

46 CORPORATE GOVERNANCE AND OTHER INFORMATION

企業管治及其他資料

COMPLIANCE WITH MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS OF LISTED ISSUERS

The Company has adopted the Model Code as set out in Appendix 10 to the Listing Rules as its own code of conduct regarding Directors' securities transactions.

The Company's relevant employees, who because of his/her office or employment, are likely to be in possession of inside information of the Company, are also subject to the Model Code. Having made specific enquiries of all the Directors and the relevant employees, they have confirmed that they have complied with the Model Code during the Reporting Period.

CHANGES IN INFORMATION OF DIRECTORS AND CHIEF EXECUTIVES

The changes in information of Directors and chief executives during the Reporting Period are set out below:

Mr. Tang Keke has resigned from his position as the chief technology officer of the Company with effect from May 2023 due to his work arrangement and will continue to hold other positions in the Group after such resignation.

Pursuant to the disclosure requirement under Rule 13.51B(1) of the Listing Rules, the changes in information of Directors are as follows:

Ms. Wang Danzhou, an independent non-executive Director, ceased to serve as an independent non-executive director of Guangdong Xiaosong Technology Co., Ltd. (formerly known as Kennede Electronics MFG. Co., Ltd), a company listed on the Shenzhen Stock Exchange (stock code: 002723), with effect from June 2023.

Save as disclosed above, since the date of the 2022 annual report of the Company and up to the date of this interim report, there has been no change to the information of the Directors and the senior management which is required to be disclosed pursuant to Rule 13.51B(1) of the Listing Rules.

遵守上市發行人董事進行證券交易的標準守則

本公司已採納上市規則附錄十所載的標準守則，作為其本身有關董事進行證券交易的行為守則。

本公司的相關僱員因職務或受僱情況而可能擁有本公司的內幕消息，亦須受標準守則規限。經向全體董事及相關僱員作出具體查詢後，彼等已確認彼等於報告期間一直遵守標準守則。

董事及高級管理層資料變更

報告期內，董事及高級管理層的資料變動如下：

唐珂軻先生因工作安排原因，自2023年5月起辭任公司首席技術官職務，辭任後繼續擔任本集團其他職務。

根據上市規則第13.51B(1)條的披露規定，董事個人資料變動情況如下：

獨立非執行董事王丹舟女士於2023年6月起不再出任廣東小崧科技股份有限公司(更名前為：廣東金萊特電器股份有限公司，一家於深圳證券交易所上市的公司，股份代號：002723)的獨立非執行董事。

除上文所披露者外，自本公司2022年年報日期起至本中期報告日期止，根據上市規則第13.51B(1)條必須披露的董事及高級管理人員資料並無發生任何變動。

CORPORATE GOVERNANCE AND OTHER INFORMATION

企業管治及其他資料

DIRECTORS' AND CHIEF EXECUTIVES' INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES

As at 30 June 2023, the interests and short positions of the Directors and chief executive of the Company in the Shares, underlying Shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO), which were required to be (i) notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they are taken or deemed to have under such provisions of the SFO), or (ii) entered in the register kept by the Company pursuant to section 352 of the SFO, or (iii) notified to the Company and the Stock Exchange under the Model Code, were as follows:

董事及最高行政人員於股份、相關股份及債權證中的權益及淡倉

於2023年6月30日，本公司董事及最高行政人員於本公司或其任何相關法團(定義見證券及期貨條例第XV部)的股份、相關股份及債權證中擁有(i)根據證券及期貨條例第XV部第7及8分部須知會本公司及聯交所的權益或淡倉(包括根據證券及期貨條例有關條文被當作或視為擁有的權益及淡倉)，或(ii)根據證券及期貨條例第352條須記入本公司存置的登記冊內的權益或淡倉，或(iii)根據標準守則須知會本公司及聯交所的權益或淡倉如下：

Long Position in the Shares

股份好倉

Name of Director or chief executive	Capacity/Nature of interest	Number of Shares	Total	Approximate percentage of interest in the Company ¹ 佔本公司的權益概約百分比 ¹
董事或最高行政人員姓名	身份／權益性質	股份數量	總計	
Mr. Wu Yushu ² 吳鬱抒先生 ²	Interest of controlled corporation 受控法團權益	248,737,500		
	Interest of spouse 配偶權益	20,250,000		
			268,987,500	59.54%
Ms. Wang Lifang ² 王莉芳女士 ²	Interest of controlled corporation 受控法團權益	87,750,000		
	Interest of spouse 配偶權益	181,237,500		
			268,987,500	59.54%

48 CORPORATE GOVERNANCE AND OTHER INFORMATION 企業管治及其他資料

Notes:

1. The calculation is based on the total number of 451,770,000 Shares in issue as at 30 June 2023.
2. Mr. Wu and Ms. Wang are the spouse of each other, and are deemed to be interested in the Shares beneficially owned by each other. Mr. Wu wholly owns Wellmark Link Limited and is deemed to be interested in the Shares held by Wellmark Link Limited. Ms. Wang wholly owns WLF Investment Holdings Limited and is deemed to be interested in the Shares held by WLF Investment Holdings Limited. Wellmark Link Limited is the general partner of Rikan Industry Investment Limited Partnership and Ms. Wang, through WLF Investment Holdings Limited, holds approximately 62.8866% interests in Rikan Industry Investment Limited Partnership. They are deemed to be interested in the Shares held by Rikan Industry Investment Limited Partnership.

Save as disclosed above, so far as the Directors are aware, as at 30 June 2023, none of the Directors or chief executive of the Company had any interest or short positions in the Shares, underlying Shares and debentures of the Company or its associated corporations (within the meaning of Part XV of the SFO) which were required to be (i) notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they are taken or deemed to have under such provisions of the SFO), or (ii) entered in the register kept by the Company pursuant to section 352 of the SFO, or (iii) notified to the Company and the Stock Exchange under the Model Code.

附註：

1. 根據2023年6月30日已發行股份總數451,770,000股計算。
2. 吳先生及王女士彼此為配偶，故被視為於彼此各自實益擁有的股份中擁有權益。吳先生全資擁有盈連有限公司，故被視為於盈連有限公司持有的股份中擁有權益。王女士全資擁有WLF Investment Holdings Limited，故被視為於WLF Investment Holdings Limited持有的股份中擁有權益。盈連有限公司為Rikan Industry Investment Limited Partnership的普通合夥人，而王女士透過WLF Investment Holdings Limited持有Rikan Industry Investment Limited Partnership約62.8866%權益。彼等被視為於Rikan Industry Investment Limited Partnership持有的股份中擁有權益。

除上文所披露者外，就董事所知，於2023年6月30日，概無董事或本公司最高行政人員於本公司或其任何相關法團（定義見證券及期貨條例第XV部）的股份、相關股份或債權證中擁有(i)根據證券及期貨條例第XV部第7及8分部須知會本公司及聯交所的權益或淡倉（包括根據證券及期貨條例有關條文被當作或視為擁有的權益及淡倉），或(ii)根據證券及期貨條例第352條須記入本公司存置的登記冊內的權益或淡倉，或(iii)根據標準守則須知會本公司及聯交所的權益或淡倉。

CORPORATE GOVERNANCE AND OTHER INFORMATION

企業管治及其他資料

SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES

As at 30 June 2023, the following persons (other than the Directors and chief executive of the Company) had an interest or short position in the Shares and underlying Shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO as recorded in the register required to be kept by the Company, pursuant to section 336 of the SFO:

主要股東於股份及相關股份中的權益及淡倉

於2023年6月30日，按本公司根據證券及期貨條例第336條須存置的登記冊所記錄，以下人士(董事及本公司最高行政人員除外)於本公司股份及相關股份中擁有根據證券及期貨條例第XV部第2及第3分部的條文須向本公司披露的權益或淡倉：

Long Position in the Shares

股份好倉

Name	Capacity/Nature of interest	Number of Shares	Total	Approximate percentage of interest in the Company ¹ 佔本公司的權益概約百分比 ¹
姓名／名稱	身份／權益性質	股份數量	總計	
Wellmark Link Limited ² 盈連有限公司 ²	Beneficial owner 實益擁有人	181,237,500		
	Interest of controlled corporation 受控法團權益	67,500,000		
			248,737,500	55.06%
WLF Investment Holdings Limited ²	Beneficial owner 實益擁有人	20,250,000		
	Interest of controlled corporation 受控法團權益	67,500,000		
			87,750,000	19.42%

50 CORPORATE GOVERNANCE AND OTHER INFORMATION
企業管治及其他資料

Name	Capacity/Nature of interest	Number of Shares	Total	Approximate percentage of interest in the Company ¹ 佔本公司的權益概約百分比 ¹
姓名/名稱	身份/權益性質	股份數量	總計	
Rikan Industry Investment Limited Partnership ²	Beneficial owner 實益擁有人	67,500,000		14.94%
Montesy Capital Holding Ltd ³	Beneficial owner 實益擁有人	68,512,500		15.17%
Ms. Wu Meirong ³ 吳美容女士 ³	Interest of spouse 配偶權益	68,512,500		15.17%
Mr. Li Hanxiong ³ 李捍雄先生 ³	Interest of controlled corporation 受控法團權益	68,512,500		15.17%
Mr. Yu Rong ⁴ 俞熔先生 ⁴	Interest of controlled corporation 受控法團權益	30,469,250		6.74%
Shanghai Tianyi Assets Management Co., Ltd ⁴ 上海天億資產管理有限公司 ⁴	Interest of controlled corporation 受控法團權益	30,469,250		6.74%
Shanghai Xuanyu Enterprise Management Co., Ltd ⁴ 上海軒瑜企業管理有限公司 ⁴	Interest of controlled corporation 受控法團權益	23,851,625		5.28%
Tianyi (BVI) Limited ⁴	Beneficial owner 實益擁有人	23,851,625		5.28%

CORPORATE GOVERNANCE AND OTHER INFORMATION
企業管治及其他資料 51

Notes:

1. The calculation is based on the total number of 451,770,000 Shares in issue as at 30 June 2023.
2. Mr. Wu and Ms. Wang are the spouse of each other, and are deemed to be interested in the Shares beneficially owned by each other. Mr. Wu wholly owns Wellmark Link Limited and is deemed to be interested in the Shares held by Wellmark Link Limited. Ms. Wang wholly owns WLF Investment Holdings Limited and is deemed to be interested in the Shares held by WLF Investment Holdings Limited. Wellmark Link Limited is the general partner of Rikan Industry Investment Limited Partnership and Ms. Wang, through WLF Investment Holdings Limited, holds approximately 62.8866% interests in Rikan Industry Investment Limited Partnership. They are deemed to be interested in the Shares held by Rikan Industry Investment Limited Partnership.
3. Montesy Capital Holding Ltd is owned by Mr. Li Hanxiong and Ms. Wu Meirong as to 70% and 30%, respectively. Mr. Li Hanxiong and Ms. Wu Meirong are the spouse of each other, and are therefore deemed to be interested in any Shares in which one another is interested. Therefore, both Li Hanxiong and Ms. Wu Meirong are deemed to be interested in the Shares held by Montesy Capital Holding Ltd.

附註：

1. 根據2023年6月30日已發行股份總數451,770,000股計算。
2. 吳先生及王女士彼此為配偶，故被視為於彼此各自實益擁有的股份中擁有權益。吳先生全資擁有盈連有限公司，故被視為於盈連有限公司持有的股份中擁有權益。王女士全資擁有WLF Investment Holdings Limited，故被視為於WLF Investment Holdings Limited持有的股份中擁有權益。盈連有限公司為Rikan Industry Investment Limited Partnership的普通合夥人，而王女士透過WLF Investment Holdings Limited持有Rikan Industry Investment Limited Partnership約62.8866%權益。彼等被視為於Rikan Industry Investment Limited Partnership持有的股份中擁有權益。
3. Montesy Capital Holding Ltd由李捍雄先生及吳美容女士分別擁有70%及30%。李捍雄先生及吳美容女士為彼此的配偶，因此被視為於彼此擁有權益的任何股份中擁有權益。因此，李捍雄及吳美容女士均被視為於Montesy Capital Holding Ltd持有的股份中擁有權益。

52 CORPORATE GOVERNANCE AND OTHER INFORMATION 企業管治及其他資料

4. Tianyi (BVI) Limited and Jiequan Zhongwei Tengyun Limited are controlled by Shanghai Tianyi Assets Management Co., Ltd as explained below. Therefore, Shanghai Tianyi Assets Management Co., Ltd is deemed to be interested in the Shares held by Tianyi (BVI) Limited and Jiequan Zhongwei Tengyun Limited. Shanghai Tianyi Assets Management Co., Ltd is in turn owned as to 70% by Mr. Yu Rong (俞熔). Therefore, Mr. Yu Rong is deemed to be interested in the Shares in which Shanghai Tianyi Assets Management Co., Ltd is deemed to be interested. Tianyi (BVI) Limited is wholly owned by Shanghai Xuanyu Enterprise Management Co., Ltd. (上海軒瑜企業管理有限公司), which is in turn wholly owned by Shanghai Tianyi Assets Management Co., Ltd. Therefore, each of Shanghai Xuanyu Enterprise Management Co., Ltd. (上海軒瑜企業管理有限公司) and Shanghai Tianyi Assets Management Co., Ltd is deemed to be interested in the Shares held by Tianyi (BVI) Limited. Jiequan Zhongwei Tengyun Limited is wholly owned by Shanghai Hongyi Enterprise Management Center (Limited Partnership) (上海鴻慧企業管理中心(有限合夥)), the sole general partner of which is Jiangsu Zhongwei Tengyun Chuangye Investment Management Co., Ltd (江蘇中衛騰雲創業投資管理有限公司) holding 8.7% interests, which is in turn controlled by Shanghai Tianyi Assets Management Co., Ltd as to 80%, and the remaining limited partner of which is Jiangsu Jiequan Zhongwei Tengyun Pharmaceutical Industrial Investment Fund (LLP) (江蘇韋泉中衛騰雲醫藥健康產業投資基金(有限合夥)) holding 91.3% interests. The sole general partner of Jiangsu Jiequan Zhongwei Tengyun Pharmaceutical Industrial Investment Fund (LLP) (江蘇韋泉中衛騰雲醫藥健康產業投資基金(有限合夥)) is Jiangsu Zhongwei Tengyun Chuangye Investment Management Co., Ltd (江蘇中衛騰雲創業投資管理有限公司) holding 1% interests, which is in turn controlled by Shanghai Tianyi Assets Management Co., Ltd. Therefore, as Jiequan Zhongwei Tengyun Limited is controlled as to 80% by Shanghai Tianyi Assets Management Co., Ltd, Shanghai Tianyi Assets Management Co., Ltd is deemed to be interested in the Shares held by Jiequan Zhongwei Tengyun Limited.
4. 如下文所闡釋，Tianyi (BVI) Limited及Jiequan Zhongwei Tengyun Limited由上海天億資產管理有限公司控制。因此，上海天億資產管理有限公司被視為於Tianyi (BVI) Limited及Jiequan Zhongwei Tengyun Limited持有的股份中擁有權益。上海天億資產管理有限公司由俞熔先生擁有70%權益。因此，俞熔先生被視為於上海天億資產管理有限公司被視作擁有權益的股份中擁有權益。Tianyi (BVI) Limited由上海軒瑜企業管理有限公司全資擁有，而後者由上海天億資產管理有限公司全資擁有。因此，上海軒瑜企業管理有限公司及上海天億資產管理有限公司各自被視為於Tianyi (BVI) Limited持有的股份中擁有權益。Jiequan Zhongwei Tengyun Limited由上海鴻慧企業管理中心(有限合夥)全資擁有，其唯一普通合夥人為江蘇中衛騰雲創業投資管理有限公司(持有8.7%權益，由上海天億資產管理有限公司控制80%股權)，而其餘下有限合夥人為江蘇韋泉中衛騰雲醫藥健康產業投資基金(有限合夥)(持有91.3%權益)。江蘇韋泉中衛騰雲醫藥健康產業投資基金(有限合夥)的唯一普通合夥人為江蘇中衛騰雲創業投資管理有限公司(持有1%權益)，而後者由上海天億資產管理有限公司控制。因此，於本中期報告日期，由於Jiequan Zhongwei Tengyun Limited由上海天億資產管理有限公司控制80%股權，故上海天億資產管理有限公司被視為於Jiequan Zhongwei Tengyun Limited持有的股份中擁有權益。

CORPORATE GOVERNANCE AND OTHER INFORMATION

企業管治及其他資料

Save as disclosed above, as at 30 June 2023, we were not aware of any persons (other than the Directors or the chief executives of the Company) who had interests or short positions in the Shares or the underlying Shares which fall to be disclosed to the Company and the Stock Exchange under the provisions of Divisions 2 and 3 of Part XV of the SFO, or which were recorded in the register required to be kept by the Company under Section 336 of the SFO.

SHARE OPTION SCHEME

The Company adopted a share option scheme by way of written resolutions of all Shareholders on 27 April 2022. The purpose of the Share Option Scheme is to provide incentive or reward to eligible persons for their contribution to, and continuing efforts to promote the interests of, the Group and for such other purposes as the Board may approve from time to time. A summary of the principal terms of the Share Option Scheme is set out in the Prospectus. The number of options available for grant under the Share Option Scheme as at the beginning and end of the Reporting Period was 45,000,000. Since the Listing Date and up to the date of this interim report, no share option was granted, exercised, expired or lapsed and there was no outstanding share option under the Share Option Scheme. Accordingly, the number of shares that may be issued in respect of options granted under the Share Option Scheme during the Reporting Period divided by the weighted average number of Shares is nil.

SHARE AWARD SCHEME

The Company adopted the Share Award Scheme on 5 December 2022. Subject to any early termination as may be determined by the Board, the Share Award Scheme shall be valid and effective for a term of ten years commencing on the adoption date, after which no further awards will be granted. Therefore, as at 30 June 2023, the remaining term of the Share Award Scheme is approximately 9 years.

The purposes and objectives of the Share Award Scheme are to recognise the contributions by certain Eligible Participants and to provide them with incentives in order to retain them for the continual operation and development of the Group; and to attract suitable personnel for further development of the Group.

除上文所披露者外，於2023年6月30日，我們概不知悉有任何人士（董事或本公司最高行政人員除外）於本公司股份及相關股份中擁有根據證券及期貨條例第XV部第2及第3分部的條文須向本公司及聯交所披露，或按本公司根據證券及期貨條例第336條須存置的登記冊所記錄的權益或淡倉。

購股權計劃

本公司於2022年4月27日經全體股東通過書面決議案採納購股權計劃。購股權計劃旨在激勵或獎勵為本集團作出貢獻及持續努力促進本集團利益的合資格人士，以及用於董事會可能不時批准的其他用途。購股權計劃的主要條款概要載於招股章程。於報告期初及期末，購股權計劃項下可供授出的購股權數目為45,000,000份。自上市日期直至本中期報告日期，概無購股權授出、行使、到期或失效，亦無在購股權計劃項下尚未行使的購股權。因此，報告期內根據購股權計劃授出的購股權可能發行的股份數目除以股份加權平均數為零。

股份獎勵計劃

本公司於2022年12月5日採納股份獎勵計劃。自採納日期起計有效期為十年，惟可由董事會決定提早終止，其後將不再授出獎勵。因此，截止2023年6月30日，股份獎勵計劃的餘下年期約為9年。

股份獎勵計劃的目的及宗旨為表彰若干合資格參與者的貢獻，為彼等提供獎勵，從而挽留彼等以助本集團的持續運營及發展；及吸引合適人員以促進本集團進一步發展。

54 CORPORATE GOVERNANCE AND OTHER INFORMATION 企業管治及其他資料

Any individual who the Board or its delegate(s) considers, in their sole discretion, to have contributed or will contribute to the Group: (i) any employees of the Group; (ii) any employees of the holding companies, fellow subsidiaries or associated companies of the Company; and (iii) any persons who provide services to any members of the Group on a continuing or recurring basis in its ordinary and usual course of business which are in the interests of the long-term growth of the Group, provided any such Eligible Participant is not a connected person of the Group. Although the Share Award Scheme allows the granting of awards to nonemployees, the Company currently has no intention to grant any award to nonemployee participants.

The Board shall not make any further grant of award such that the total number of Shares granted under the Share Award Scheme will exceed 10% of the total number of issued Shares as of the adoption date. On the basis that the total number of issued Shares as of the adoption date is 451,770,000 Shares, the aforesaid 10% limit represents a total of 45,177,000 Shares.

Since 5 December 2022 and up to 30 June 2023, the Trustee, as instructed by the Board, purchased a total of 21,751,500 Shares on the market, representing approximately 4.81% of the total number of Shares of the Company in issue. The Trustee holds these Shares in accordance with to the Scheme Rules and the Trust Deed. The number of awards available for grant under the Share Award Scheme as at the beginning and end of the Reporting Period was 45,177,000. As at 30 June 2023, no award was granted by the Company, nor any award was exercised, canceled or lapsed under the Share Award Scheme, and there was no award outstanding under the Share Award Scheme as at the above date. Accordingly, the number of Shares that may be issued in respect of awards granted under the Share Award Scheme during the Reporting Period divided by the weighted average number of Shares is nil.

董事會或其授權代表全權酌情認為已經或將會對本集團有貢獻的任何個人：(i)本集團的任何僱員；(ii)本公司的控股公司、同系附屬公司或聯營公司的任何僱員；(iii)於本集團的一般及日常業務過程中，持續或經常性地向本集團任何成員公司提供對本集團長期發展有利的服務的任何參與者，惟任何合資格參與者並非本集團之關連人士。儘管股份獎勵計劃允許向非僱員授出獎勵，但本公司目前無意向非僱員參與者授出任何獎勵。

董事會進一步授出的任何獎勵不得導致根據股份獎勵計劃授出的股份總數超過截至採納日期已發行股份總數的10%。基於截至採納日期已發行股份總數為451,770,000股股份，上述10%限額相當於合共45,177,000股股份。

自2022年12月5日起至2023年6月30日止，受託人按照董事會的指示在市場上購買合共21,751,500股股份（相當於本公司已發行股份總數約4.81%），受託人根據計劃規則及信託契據條款持有該筆股份。於報告期初及期末，股份獎勵計劃項下可供授出的獎勵數目為45,177,000份。截至2023年6月30日止，本公司概無根據股份獎勵計劃獲授予、行使、註銷或失效，截至該日期亦無尚未行使的股份獎勵。因此，報告期內根據股份獎勵計劃授出的獎勵可能發行的股份數目除以股份加權平均數為零。

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES OF THE COMPANY

Neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company's listed securities since the Listing Date and up to the date of this interim report.

INTERIM DIVIDEND

The Board resolved not to declare the payment of any interim dividend for the six months ended 30 June 2023 (For the six months ended 30 June 2022: nil).

AUDIT COMMITTEE

The Audit Committee, consisting of three independent non-executive Directors, namely, Mr. Wei Bin (Chairman), Ms. Wang Danzhou and Ms. Du Yilin, has reviewed the unaudited interim results of the Group for the six months ended 30 June 2023, including the accounting principles and practices adopted by the Group and confirmed that it has complied with all applicable accounting principles, standards and requirements and made full disclosure. The unaudited interim results of the Group were not reviewed by the external auditors of the Company.

USE OF PROCEEDS FROM THE GLOBAL OFFERING

The Shares of the Company have been listed on the Main Board of the Stock Exchange since 12 July 2022. The Group received net proceeds (including the partial exercise of the over-allotment option and after deduction of underwriting commissions and related costs and expenses) from the Global Offering of approximately HK\$339.6 million (the "**Net Proceeds**"). The Group will continue to utilise the Net Proceeds as set out in the section headed "Future Plans and Use of Proceeds" in the Prospectus. The intended application of the Net Proceeds as stated in the Prospectus and the actual utilisation of the Net Proceeds from the Listing Date up to the date of this interim report is set out below:

購買、出售或贖回本公司上市證券

自上市日期直至本中期報告日期，本公司或其任何附屬公司概無購買、出售或贖回本公司任何上市證券。

中期股息

董事已議決不宣派截至2023年6月30日止六個月的任何中期股息(截至2022年6月30日止六個月：零)。

審核委員會

由三位獨立非執行董事(即魏斌先生(主席)、王丹舟女士及杜依琳女士)組成的審核委員會，已審閱本集團截至2023年6月30日止六個月的未經審核中期業績，包括本集團所採納的會計原則及慣例，並確認已遵守所有適用會計原則、準則及規則和作出充份披露。本集團的未經審核中期業績未經本公司外聘核數師審閱。

全球發售所得款項用途

本公司股份於2022年7月12日在聯交所主板上市。本集團從全球發售中獲得現金款項淨額(包括超額配股權的部分行使及經扣除包銷佣金及相關費用和開支)約339.6百萬港元(「**所得款項淨額**」)。本集團將繼續按招股章程「未來計劃及所得款項用途」一節所載方式動用所得款項淨額。自上市日期直至本中期報告日期，招股章程所述所得款項淨額擬定用途及所得款項淨額的實際動用情況如下：

56 CORPORATE GOVERNANCE AND OTHER INFORMATION
企業管治及其他資料

Planned Use of Net Proceeds	Approximate percentage of the Net Proceeds	Actual Allocation of the Net Proceeds	Utilised Net Proceeds as at 30 June 2023 截至2023年6月30日 已動用 所得款項淨額 (HK\$ million) (百萬港元)	Unutilised Net Proceeds as at 30 June 2023 截至2023年6月30日 尚未動用的 所得款項淨額 (HK\$ million) (百萬港元)	Expected timeline for the use of the unutilised Net Proceeds
所得款項淨額 計劃用途	佔所得款項 淨額的概約 百分比	實際獲分配 所得款項 淨額 (HK\$ million) (百萬港元)	所得款項淨額 (HK\$ million) (百萬港元)	所得款項淨額 (HK\$ million) (百萬港元)	預期動用尚未動用 所得款項淨額的時間
Upgrade and enhance SaaS products 升級及提升SaaS產品	50.8%	172.5	12.7	159.8	By 31 December 2025 2025年12月31日以前
Conduct further research and development of the Group's technology and data warehouse 對本集團的技術及數據倉庫作進一步研發	49.2%	167.1	8.1	159.0	By 31 December 2025 2025年12月31日以前
Total 合計	100%	339.6	20.8	318.8	

During the Reporting Period, the Net Proceeds have been and will be used in accordance with the purposes set out in the Prospectus, and there has been no material change or delay in the use of the Net Proceeds.

報告期內，所得款項淨額已及將根據招股章程所載用途使用，且所得款項淨額用途並無重大變動或延誤。

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
 中期簡明綜合損益及其他全面收益表

For the six months ended 30 June 2023
 截至2023年6月30日止六個月

		Notes	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元	2022 2022年 (Unaudited) (未經審核) RMB'000 人民幣千元
REVENUE	收入	4	144,950	121,209
Cost of sales	銷售成本		(69,768)	(64,558)
Gross profit	毛利		75,182	56,651
Other income and gains	其他收入及收益	4	35,816	10,861
Selling and distribution expenses	銷售及分銷開支		(15,109)	(15,096)
Administrative expenses	行政開支		(15,121)	(18,725)
Research and development costs	研發成本		(27,229)	(28,520)
Impairment losses on financial assets, net	金融資產減值虧損淨額		(5,361)	(1,021)
Other expenses	其他開支		(8)	(10)
Finance costs	財務成本		(278)	(214)
PROFIT BEFORE TAX	除稅前溢利	5	47,892	3,926
Income tax (expense)/credit	所得稅(開支)/抵免	6	(922)	1,361
PROFIT FOR THE PERIOD	期內溢利		46,970	5,287
Attributable to:	以下各項應佔：			
Owners of the parent	母公司擁有人		47,833	3,860
Non-controlling interests	非控股權益		(863)	1,427
			46,970	5,287
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	期內全面收益總額		46,970	5,287

58 INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
 中期簡明綜合損益及其他全面收益表

For the six months ended 30 June 2023

截至2023年6月30日止六個月

		Notes	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元	2022 2022年 (Unaudited) (未經審核) RMB'000 人民幣千元
		附註		
Attributable to:	以下各項應佔：			
Owners of the parent	母公司擁有人		47,833	3,860
Non-controlling interests	非控股權益		(863)	1,427
			46,970	5,287
EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT	母公司普通股權益持有 人應佔每股盈利			
Basic and diluted	基本及攤薄	8	0.11	0.01

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

中期簡明綜合財務狀況表

30 June 2023
2023年6月30日

		Notes	30 June 2023 2023年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2022 2022年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
		附註		
NON-CURRENT ASSETS	非流動資產			
Property, plant and equipment	物業、廠房及設備	9	4,733	4,383
Right-of-use assets	使用權資產		15,904	6,854
Other intangible assets	其他無形資產		1,254	1,590
Time deposits	定期存款	12	162,746	80,772
Deferred tax assets	遞延稅項資產		1,623	686
Total non-current assets	非流動資產總值		186,260	94,285
CURRENT ASSETS	流動資產			
Inventories	存貨		3,360	2,317
Trade and notes receivables	貿易應收款項及應收票據	10	73,768	91,993
Prepayments, other receivables and other assets	預付款項、其他應收款項及其他資產		20,014	20,988
Financial assets at fair value through profit or loss	按公平值計入損益的金融資產	11	46,797	2,098
Time deposits	定期存款	12	320,292	175,474
Cash and cash equivalents	現金及現金等價物	12	199,194	409,318
Total current assets	流動資產總值		663,425	702,188
CURRENT LIABILITIES	流動負債			
Trade payables	貿易應付款項	13	8,989	14,665
Other payables and accruals	其他應付款項及應計款項	14	103,635	74,139
Lease liabilities	租賃負債		2,798	3,223
Due to a related party	應付一名關聯方款項	17	157	355
Tax payable	應付稅項		1,639	5,407
Total current liabilities	流動負債總額		117,218	97,789

60 INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

中期簡明綜合財務狀況表

30 June 2023
2023年6月30日

		Notes	30 June 2023 2023年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2022 2022年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
		附註		
NET CURRENT ASSETS	流動資產淨值		546,207	604,399
TOTAL ASSETS LESS CURRENT LIABILITIES	資產總值減流動負債		732,467	698,684
NON-CURRENT LIABILITIES	非流動負債			
Lease liabilities	租賃負債		13,890	3,904
Deferred tax liabilities	遞延稅項負債		–	1,544
Total non-current liabilities	非流動負債總額		13,890	5,448
Net assets	資產淨值		718,577	693,236
EQUITY	股權			
Equity attributable to owners of the parent	母公司擁有人應佔股權			
Share capital	股本	16	30,384	30,384
Treasury shares	庫存股份	16	(106,997)	(101,121)
Reserves	儲備		797,855	765,775
			721,242	695,038
Non-controlling interests	非控股權益		(2,665)	(1,802)
Total equity	總權益		718,577	693,236

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

中期簡明綜合權益變動表

61

For the six months ended 30 June 2023
截至2023年6月30日止六個月

		Attributable to owners of the parent 母公司擁有人應佔						Non-controlling interest		Total equity
		Share capital	Treasury shares	Share premium*	Capital reserve*	Statutory reserve*	Retained profits*	Total	Non-controlling interest	Total equity
		股本	庫存股份	股份溢價*	資本儲備*	法定儲備*	保留溢利*	總計	非控股權益	總權益
		RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
		人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元	人民幣千元
At 1 January 2023	於2023年1月1日	30,384	(101,121)	477,339	19,372	29,556	239,508	695,038	(1,802)	693,236
Total comprehensive income for the period	期內全面收入總額	-	-	-	-	-	47,833	47,833	(863)	46,970
Shares repurchased	購回股份	-	(5,876)	-	-	-	-	(5,876)	-	(5,876)
Dividends declared	已宣派股息	-	-	-	-	-	(15,753)	(15,753)	-	(15,753)
At 30 June 2023 (unaudited)	於2023年6月30日 (未經審核)	30,384	(106,997)	477,339	19,372	29,556	271,588	721,242	(2,665)	718,577

62 INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY 中期簡明綜合權益變動表

For the six months ended 30 June 2023

截至2023年6月30日止六個月

		Attributable to owners of the parent 母公司擁有人應佔					Non-controlling interests		Total equity
		Share capital 股本	Share premium* 股份溢價*	Capital reserve* 資本儲備*	Statutory reserve* 法定儲備*	Retained profits* 保留溢利*	Total 總計	Non-controlling interests 非控股權益	Total equity 總權益
		RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元	RMB'000 人民幣千元
At 1 January 2022	於2022年1月1日	322	183,858	19,372	24,532	188,774	416,858	(947)	415,911
Total comprehensive income for the period	期內全面收入總額	-	-	-	-	3,860	3,860	1,427	5,287
At 30 June 2022 (unaudited)	於2022年6月30日(未經審核)	322	183,858	19,372	24,532	192,634	420,718	480	421,198

* These reserve accounts comprise the consolidated reserves of RMB797,855,000 (30 June 2022: RMB420,396,000) in the unaudited interim condensed consolidated statement of financial position as at 30 June 2023.

* 該等儲備賬包括於2023年6月30日的未經審核中期簡明綜合財務狀況表內的綜合儲備人民幣797,855,000元(2022年6月30日：人民幣420,396,000元)。

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

中期簡明綜合現金流量表

For the six months ended 30 June 2023
截至2023年6月30日止六個月

		Notes	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元	2022 2022年 (Unaudited) (未經審核) RMB'000 人民幣千元
		附註		
CASH FLOWS FROM	經營活動之現金流量			
OPERATING ACTIVITIES				
Profit before tax	除稅前溢利		47,892	3,926
Adjustments for:	就以下各項調整：			
Finance costs	財務成本		278	214
Bank interest income	銀行利息收入	4	(12,521)	(78)
Investment income from financial assets at fair value through profit or loss	按公平值計入損益的金融資產的投資收入	4	(20)	(2,842)
Fair value gains on financial assets at fair value through profit or loss	按公平值計入損益的金融資產公平值收益	4	(209)	(3,425)
Depreciation of property, plant and equipment	物業、廠房及設備折舊	9	1,242	1,213
Depreciation of right-of-use assets	使用權資產折舊		2,890	2,430
Amortisation of other intangible assets	其他無形資產攤銷		430	335
Gains on lease modifications	租賃修改收益	4	(14)	-
Impairment of trade receivables	貿易應收款項減值	10	5,361	1,021
Foreign exchange gains, net	外匯收益淨額	4	(14,445)	(277)
Loss on disposal of items of property, plant and equipment	出售物業、廠房及設備項目的虧損		1	4

64 INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS 中期簡明綜合現金流量表

For the six months ended 30 June 2023
截至2023年6月30日止六個月

		Notes 附註	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元	2022 2022年 (Unaudited) (未經審核) RMB'000 人民幣千元
Decrease in trade and notes receivables	貿易應收款項及應收票據減少		12,864	10,898
Decrease/(increase) in prepayments, other receivables and other assets	預付款項、其他應收款項及其他資產減少／(增加)		569	(5,277)
Decrease in due from a related party	應收一名關聯方款項減少		–	73
Increase in inventories	存貨增加		(1,043)	(1,980)
Decrease in due to a related party	應付一名關聯方款項減少		(198)	–
Decrease in trade payables	貿易應付款項減少		(5,676)	(7,052)
Increase in other payables and accruals	其他應付款項及應計款項增加		13,743	3,606
Cash generated from operations	經營所得現金		51,144	2,789
Interest received	已收利息		3,485	78
Income tax paid	已付所得稅		(7,171)	(1,024)
Net cash flows from operating activities	經營活動所得現金流量淨額		47,458	1,843

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

中期簡明綜合現金流量表

For the six months ended 30 June 2023
截至2023年6月30日止六個月

			2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元	2022 2022年 (Unaudited) (未經審核) RMB'000 人民幣千元
	Notes 附註			
CASH FLOWS FROM INVESTING ACTIVITIES		投資活動之現金流量		
Purchases of items of property, plant and equipment and related advance payments		購買物業、廠房及設備項目以及相關墊款付款	(1,594)	(969)
Proceeds from disposals of items of property, plant and equipment		出售物業、廠房及設備項目所得款項	1	73
Additions to other intangible assets		其他無形資產添置	(94)	(306)
Proceeds from disposal of an associate		出售一家聯營公司所得款項	-	184
Purchases of financial assets at fair value through profit or loss		購買按公平值計入損益的金融資產	(49,000)	(475,343)
Purchases of time deposits		購買定期存款	(210,020)	-
Investment income received from financial assets at fair value through profit or loss		按公平值計入損益的金融資產獲得的投資收入	20	2,842
Disposal of financial assets at fair value through profit or loss		出售按公平值計入損益的金融資產	4,510	539,908
Net cash flows (used in)/from investing activities		投資活動(所用)/所得現金流量淨額	(256,177)	66,389
CASH FLOWS FROM FINANCING ACTIVITIES		融資活動之現金流量		
Principal portion of lease payments		租賃付款的本金部分	(2,365)	(2,581)
Interest paid for lease liabilities		就租賃負債支付利息	(278)	(214)
Payment for listing expenses		上市開支付款	-	(1,198)
Repurchase of shares		購回股份	(5,471)	-
Net cash flows used in financing activities		融資活動所用現金流量淨額	(8,114)	(3,993)

66 INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

中期簡明綜合現金流量表

For the six months ended 30 June 2023

截至2023年6月30日止六個月

		Notes 附註	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元	2022 2022年 (Unaudited) (未經審核) RMB'000 人民幣千元
NET (DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS	現金及現金等價物(減 少)/增加淨額		(216,833)	64,239
Cash and cash equivalents at beginning of period	期初現金及現金等價物		409,318	33,955
Effect of foreign exchange rate changes, net	外匯匯率變動影響淨額		6,709	277
CASH AND CASH EQUIVALENTS AT END OF PERIOD	期末現金及現金等價物		199,194	98,471
ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS	現金及現金等價物結餘 分析			
Cash and bank balances	現金及銀行結餘		199,194	98,471
Cash and cash equivalents as stated in the interim condensed consolidated statement of financial position and the interim condensed consolidated statements of cash flow	於中期簡明綜合財務狀 況表及中期簡明綜合 現金流量表列賬的現 金及現金等價物		199,194	98,471

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

1. CORPORATE INFORMATION

The Company is a limited liability company incorporated in the Cayman Islands on 4 March 2019. The registered address of the Company is at the office of Ogier Global (Cayman) Limited, of 89 Nexus Way, Grand Cayman, KY1-9009, Cayman Islands.

The Company is an investment holding company. During the reporting period, the Company's subsidiaries were principally engaged in the provision of Data Insight Solutions, Data-driven Publications and Events and SaaS products.

The shares of the Company were listed on the Main Board of The Stock Exchange of Hong Kong Limited on 12 July 2022.

2. BASIS OF PREPARATION AND CHANGES TO THE GROUP'S ACCOUNTING POLICIES

2.1 Basis of preparation

The interim condensed consolidated financial information for the six months ended 30 June 2023 has been prepared in accordance with Hong Kong Accounting Standard ("HKAS") 34 *Interim Financial Reporting*. The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 December 2022.

1. 公司資料

本公司為一間於2019年3月4日於開曼群島註冊成立的有限公司。本公司的註冊地址位於Ogier Global (Cayman) Limited的辦事處，即89 Nexus Way, Grand Cayman, KY1-9009, Cayman Islands。

本公司為投資控股公司。於報告期，本公司的附屬公司主要從事提供數據洞察解決方案、數據驅動發佈及活動以及SaaS產品。

本公司股份於2022年7月12日在香港聯交所主板上市。

2. 編製基準及本集團會計政策變動

2.1 編製基準

截至2023年6月30日止六個月的中期簡明綜合財務資料乃根據香港會計準則(「香港會計準則」)第34號*中期財務報告編製*。中期簡明綜合財務資料並不包括年度財務報表規定須予披露之所有資料及披露資料，並應與本集團截至2022年12月31日止年度的年度綜合財務報表一併閱讀。

68 NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION
 中期簡明綜合財務資料附註

2. BASIS OF PREPARATION AND CHANGES TO THE GROUP'S ACCOUNTING POLICIES (continued)

2.2 Changes in accounting policies

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group's annual consolidated financial statements for the year ended 31 December 2022, except for the adoption of the following new and revised Hong Kong Financial Reporting Standards ("HKFRSs") for the first time for the current period's financial information.

HKFRS 17
 香港財務報告準則第17號
 Amendments to HKFRS 17
 香港財務報告準則第17號(修訂本)
 Amendment to HKFRS 17

 香港財務報告準則第17號(修訂本)

 Amendments to HKAS 1 and HKFRS
 Practice Statement 2
 香港會計準則第1號及香港財務報告
 準則實務公告第2號(修訂本)
 Amendments to HKAS 8
 香港會計準則第8號(修訂本)
 Amendments to HKAS 12

 香港會計準則第12號(修訂本)

 Amendments to HKAS 12
 香港會計準則第12號(修訂本)

2. 編製基準及本集團會計政策變動(續)

2.2 會計政策變動

編製中期簡明綜合財務資料所採納的會計政策與編製本集團截至2022年12月31日止年度的年度綜合財務報表所採納者一致，惟本期間的財務資料首次採納以下新訂及經修訂香港財務報告準則(「香港財務報告準則」)除外。

Insurance Contracts
 保險合約
Insurance Contracts
 保險合約
Initial Application of HKFRS 17 and HKFRS 9 – Comparative Information
 首次應用香港財務報告準則第17號及香港財務報告準則第9號—可比較資料
Disclosure of Accounting Policies
 披露會計政策
Definition of Accounting Estimates
 會計估計的定義
Deferred Tax related to Assets and Liabilities arising from a Single Transaction
 與單一交易產生的資產及負債相關的遞延稅項
International Tax Reform – Pillar Two Model Rules
 國際稅務改革—支柱二示範規則

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

2. BASIS OF PREPARATION AND CHANGES TO THE GROUP'S ACCOUNTING POLICIES (continued)

2.2 Changes in accounting policies (continued)

The nature and impact of the new and revised HKFRSs that are applicable to the Group are described below:

- (a) Amendments to HKAS 1 require entities to disclose their material accounting policy information rather than their significant accounting policies. Accounting policy information is material if, when considered together with other information included in an entity's financial statements, it can reasonably be expected to influence decisions that the primary users of general purpose financial statements make on the basis of those financial statements. Amendments to HKFRS Practice Statement 2 provide non-mandatory guidance on how to apply the concept of materiality to accounting policy disclosures. The Group has applied the amendments since 1 January 2023. The amendments did not have any impact on the Group's interim condensed consolidated financial information but are expected to affect the accounting policy disclosures in the Group's annual consolidated financial statements.

2. 編製基準及本集團會計政策變動(續)

2.2 會計政策變動(續)

適用於本集團的新訂及經修訂香港財務報告準則的性質及影響如下文所述：

- (a) 香港會計準則第1號(修訂本)要求實體披露其重大會計政策資料，而非其重要會計政策。如果會計政策資料與實體財務報表中包含的其他資料一起考慮時，可以合理地預期會影響通用財務報表的主要使用者根據這些財務報表作出的決策，則該資料是重要的。對香港財務報告準則實務公告第2號的修訂為如何將重要性概念應用於會計政策披露提供了非強制性指導。本集團已自2023年1月1日起應用該等修訂。該等修訂對本集團的中期簡明綜合財務資料並無任何影響，惟預計會影響本集團年度綜合財務報表中的會計政策披露。

70 NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION
中期簡明綜合財務資料附註

2. BASIS OF PREPARATION AND CHANGES TO THE GROUP'S ACCOUNTING POLICIES (continued)

2.2 Changes in accounting policies (continued)

- (b) Amendments to HKAS 8 clarify the distinction between changes in accounting estimates and changes in accounting policies. Accounting estimates are defined as monetary amounts in financial statements that are subject to measurement uncertainty. The amendments also clarify how entities use measurement techniques and inputs to develop accounting estimates. The Group has applied the amendments to changes in accounting policies and changes in accounting estimates that occur on or after 1 January 2023. Since the Group's policy of determining accounting estimates aligns with the amendments, the amendments did not have any impact on the financial position or performance of the Group.

2. 編製基準及本集團會計政策變動(續)

2.2 會計政策變動(續)

- (b) 香港會計準則第8號(修訂本)澄清會計估計變更與會計政策變更之間的區別。會計估計的定義為財務報表中存在計量不確定性的貨幣金額。該等修訂亦澄清實體如何使用計量方法及輸入數據編製會計估計。本集團已將該等修訂應用到於2023年1月1日或之後發生的會計政策變更及會計估計變更。由於本集團確定會計估計的政策與該等修訂一致，該等修訂對本集團的財務狀況或業績並無任何影響。

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION
中期簡明綜合財務資料附註**2. BASIS OF PREPARATION AND CHANGES TO THE GROUP'S ACCOUNTING POLICIES (continued)****2.2 Changes in accounting policies (continued)**

- (c) Amendments to HKAS 12 *Deferred Tax related to Assets and Liabilities arising from a Single Transaction* narrow the scope of the initial recognition exception in HKAS 12 so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences, such as leases and decommissioning obligations. Therefore, entities are required to recognise a deferred tax asset (provided that sufficient taxable profit is available) and a deferred tax liability for temporary differences arising from these transactions. Since the Group has applied the amendments on temporary differences related to leases from beginning, the amendments did not have any impact on the financial position or performance of the Group.

2. 編製基準及本集團會計政策變動(續)**2.2 會計政策變動(續)**

- (c) 香港會計準則第12號(修訂本)與單一交易產生的資產及負債相關的遞延稅項縮小了香港會計準則第12號中初始確認例外情況的範圍，使其不再適用於產生相等應課稅及可扣減暫時差額的交易，例如租賃及停用責任。因此，實體須就該等交易產生的暫時差額確認遞延稅項資產(前提是有足夠應課稅溢利)及遞延稅項負債。由於本集團自一開始已應用與租賃相關的暫時產額的修訂，該等修訂對本集團的財務狀況或表現並無任何影響。

72 NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION
中期簡明綜合財務資料附註**2. BASIS OF PREPARATION AND CHANGES TO THE GROUP'S ACCOUNTING POLICIES (continued)****2.2 Changes in accounting policies (continued)**

- (d) Amendments to HKAS 12 *International Tax Reform – Pillar Two Model Rules* introduce a mandatory temporary exception from the recognition and disclosure of deferred taxes arising from the implementation of the Pillar Two model rules published by the Organisation for Economic Co-operation and Development. The amendments also introduce disclosure requirements for the affected entities to help users of the financial statements better understand the entities' exposure to Pillar Two income taxes, including the disclosure of current tax related to Pillar Two income taxes separately in the periods when Pillar Two legislation is effective and the disclosure of known or reasonably estimable information of their exposure to Pillar Two income taxes in periods in which the legislation is enacted or substantively enacted but not yet in effect. Entities are required to disclose the information relating to their exposure to Pillar Two income taxes in annual periods beginning on or after 1 January 2023, but are not required to disclose such information for any interim periods ending on or before 31 December 2023. The Group has applied the amendments retrospectively. Since the Group did not fall within the scope of the Pillar Two model rules, the amendments did not have any impact to the Group.

2. 編製基準及本集團會計政策變動(續)**2.2 會計政策變動(續)**

- (d) 香港會計準則第12號(修訂本)*國際稅務改革—支柱二示範規則*引入因實施經濟合作暨發展組織公佈的支柱二示範規則而產生的遞延稅項的確認及披露的強制性臨時例外情況。該等修訂亦引入對受影響實體的披露要求以幫助財務報表的使用者更好地了解實體所面臨的支柱二所得稅風險，包括在支柱二立法生效期間單獨披露與支柱二所得稅相關的即期稅項，以及在立法已頒佈或實質上已頒佈但尚未生效期間披露支柱二所得稅風險的已知或可合理估計的資料。實體須於2023年1月1日或之後開始的年度期間披露與支柱二所得稅風險有關的資料，惟毋須就截至2023年12月31日或之前止的任何中期期間披露此類資料。本集團已追溯應用該等修訂。由於本集團不屬於支柱二示範規則的範圍，該等修訂對本集團並無任何影響。

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

3. OPERATING SEGMENT INFORMATION

For management purposes, the Group is not organised into business units based on their services and only has one reportable operating segment. Management monitors the operating results of the Group's operating segment as a whole for the purpose of making decisions about resource allocation and performance assessment.

4. REVENUE, OTHER INCOME AND GAINS

An analysis of revenue is as follows:

3. 經營分部資料

就管理而言，本集團並無按其服務劃分業務單位，並僅有一個可呈報經營分部。管理層對本集團經營分部的經營業績進行全盤監控，以就資源分配及績效評估作出決策。

4. 收入、其他收入及收益

收入分析如下：

		For the six months ended 30 June	
		截至6月30日止六個月	
		2023	2022
		2023年	2022年
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
		RMB'000	RMB'000
		人民幣千元	人民幣千元
Revenue from contracts with customers	客戶合約收入	144,950	121,209

74 NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION
 中期簡明綜合財務資料附註

4. REVENUE, OTHER INCOME AND GAINS (continued)

Revenue from contracts with customers

(a) Disaggregated revenue information

客戶合約收入

(a) 分類收入資料

		For the six months ended 30 June 截至6月30日止六個月	
		2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元	2022 2022年 (Unaudited) (未經審核) RMB'000 人民幣千元
Type of goods or services by product categories	按產品類型劃分的貨品或服務類別		
Data Insight Solutions	數據洞察解決方案	88,692	83,552
Data-driven Publications and Events	數據驅動發佈及活動	32,107	21,021
SaaS products	SaaS產品	24,151	16,636
		144,950	121,209
Type of goods or services by application scenarios	按應用場景劃分的貨品或服務類別		
Smart Decision Cloud	智慧決策雲	72,073	54,351
Smart Retail Cloud	智慧零售雲	43,834	46,257
Smart Medical Cloud	智慧醫療雲	23,314	19,964
Smart Health Management Cloud	智慧健康管理雲	5,729	637
		144,950	121,209
Geographical markets	地理市場		
Mainland China	中國內地	144,782	121,076
Overseas	海外	168	133
		144,950	121,209
Timing of revenue recognition	收入確認的時間		
Services transferred at a point in time	於某一時間點轉移的服務	78,426	59,659
Services transferred over time	隨時間轉移的服務	66,524	61,550
		144,950	121,209

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

4. REVENUE, OTHER INCOME AND GAINS (continued)

Revenue from contracts with customers (continued)

(b) Performance obligations

Information about the Group's performance obligations is summarised below:

Data Insight Solutions

The performance obligation for delivery of customised research reports is generally satisfied at the point of time when the individual research report is delivered and accepted by the customers and payment is generally due within 120 days from the date of billing. The performance obligation for provision of individual marketing solution is satisfied over time as services are rendered and payment in advance is normally required.

Data-driven Publications and Events

The performance obligation is satisfied over time as services are rendered, where payment in advance is normally required. The services related to Data-driven Publications and Events are generally completed within one week.

SaaS products

The performance obligation for granting right to access the proprietary cloud-based software is satisfied over time as services are rendered, where payment in advance is normally required. The performance obligation for API use is satisfied at the point of time when the right to use is granted and payment is generally due immediately. The performance obligation for application software development is satisfied at the point of time when the application software together with relevant license is accepted by the customers, and payment is generally due when the service was completed.

4. 收入、其他收入及收益(續)

客戶合約收入(續)

(b) 履約責任

有關本集團履約責任的資料概述如下：

數據洞察解決方案

交付量身定制的研究報告的履約責任一般於個別研究報告交付並獲客戶接納時達成，付款一般自發票日期起120日內到期。提供個別營銷解決方案的履約責任隨著提供服務的時間達成，且一般須提前付款。

數據驅動發佈及活動

履約責任隨著提供服務的時間達成，惟一般須提前付款。與數據驅動發佈及活動相關的服務一般於一星期內完成。

SaaS產品

授權接入專有雲端軟件的履約責任隨時間於提供服務時達成，在此情況下一般要求提前付款。使用API的履約責任於授出使用權的時間點履行，且通常要求即時付款。應用軟件開發的履約責任於應用軟件連同相關學科組獲客戶接受的時間點達成，而付款通常於服務完成時到期。

76 NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION
 中期簡明綜合財務資料附註

4. REVENUE, OTHER INCOME AND GAINS (continued) **4. 收入、其他收入及收益(續)**

An analysis of other income and gains is as follows:

其他收入及收益的分析如下：

		For the six months ended 30 June 截至6月30日止六個月	
		2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元	2022 2022年 (Unaudited) (未經審核) RMB'000 人民幣千元
Other income	其他收入		
Bank interest income	銀行利息收入	12,521	78
Government grants*	政府補助*	8,206	3,791
Investment income from financial assets at fair value through profit or loss	按公平值計入損益的金融資產的投資收入	20	2,842
Others	其他	227	448
		20,974	7,159
Gains	收益		
Fair value gains on financial assets at fair value through profit or loss	按公平值計入損益的金融資產的公平值收益	209	3,425
Foreign exchange gains, net	匯兌收益淨額	14,445	277
Gains on lease modifications	租賃修改收益	14	-
Others	其他	174	-
		35,816	10,861

* The government grants mainly represent incentives awarded by the local governments to support the Group's operation. There were no unfulfilled conditions or contingencies attached to these grants.

* 政府補助主要指獲當地政府授予的獎勵，以支持本集團營運。該等獎勵並無附帶未履行條件或或然事項。

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

5. PROFIT BEFORE TAX

The Group's profit before tax is arrived at after charging/(crediting):

5. 除稅前溢利

本集團的除稅前溢利於扣除／(計入)以下各項後達致：

		For the six months ended 30 June 截至6月30日止六個月	
		2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元	2022 2022年 (Unaudited) (未經審核) RMB'000 人民幣千元
Cost of services provided	提供服務成本	69,768	64,558
Depreciation of property, plant and equipment	物業、廠房及設備折舊	1,242	1,213
Depreciation of right-of-use assets	使用權資產折舊	2,890	2,430
Amortisation of other intangible assets	其他無形資產攤銷	430	335
Research and development costs	研發成本	27,229	28,520
Listing expenses	上市開支	-	4,190
Lease payments not included in the measurement of lease liabilities	不計入租賃負債計量的租賃付款	50	58
Bank interest income	銀行利息收入	(12,521)	(78)
Government grants	政府補助	(8,206)	(3,791)
Investment income from financial assets at fair value through profit or loss	按公平值計入損益的金融資產的投資收入	(20)	(2,842)
Fair value gains on financial assets at fair value through profit or loss	按公平值計入損益的金融資產的公平值收益	(209)	(3,425)
Gains on lease modifications	租賃修改收益	(14)	-
Foreign exchange gains, net	匯兌收益淨額	(14,445)	(277)
Loss on disposal of items of property, plant and equipment	出售物業、廠房及設備項目之虧損	1	4
Impairment of trade receivables, net	貿易應收款項減值淨額	5,361	1,021

78 NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION 中期簡明綜合財務資料附註

6. INCOME TAX

The Group is subject to income tax on an entity basis on profit arising in or derived from the jurisdictions in which members of the Group are domiciled and operate.

Pursuant to the rules and regulations of the Cayman Islands and the BVI, the Company and its subsidiary are not subject to any income tax in the Cayman Islands and the BVI.

The statutory tax rate for the subsidiary in Hong Kong is 16.5%. No Hong Kong profits tax on the subsidiary has been provided as there was no assessable profit arising in Hong Kong during the period.

The statutory tax rate for the subsidiary in Singapore is 17%. No Singapore profits tax on the subsidiary has been provided as there was no assessable profit arising in Singapore during the period.

The provision for current income tax in Mainland China is based on a statutory tax rate of 25% of the assessable profits of the PRC subsidiaries of the Group as determined in accordance with the PRC Corporate Income Tax Law.

Guangzhou Sinohealth Information Co., Ltd. ("Sinohealth Information") was accredited as a high and new technology enterprise ("HNTE") in 2019, and the certifications were valid for three years. Sinohealth Information did not renew the HNTE Certificate in 2022, thus could no longer enjoy the preferential income tax rate of 15%. For the six months ended 30 June 2023, Sinohealth Information was entitled to a PRC Corporate Income tax rate of 25% (30 June 2022: 15%).

6. 所得稅

本集團須就本集團成員公司所處及經營所在司法權區產生或賺取的溢利，按實體基準繳納所得稅。

根據開曼群島及英屬處女群島的規則及法規，本公司及其附屬公司毋須於開曼群島及英屬處女群島繳納任何所得稅。

香港附屬公司的法定稅率為16.5%。由於期內並無於香港產生應課稅溢利，故並無就附屬公司計提香港利得稅撥備。

新加坡附屬公司的法定稅率為17%。由於期內並無於新加坡產生應課稅溢利，故並無就附屬公司計提新加坡利得稅撥備。

中國內地即期所得稅撥備乃按根據中國企業所得稅法釐定的本集團中國附屬公司的應課稅溢利按法定稅率25%釐定。

廣州中康資訊股份有限公司（「中康資訊」）於2019年被認定為高新技術企業（「HNTE」），證書有效期為三年。中康資訊於2022年並無重續HNTE證書，因此不會再享有15%的優惠所得稅稅率。截至2023年6月30日止六個月，中康資訊享有25%的中國企業所得稅稅率（2022年6月30日：15%）。

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

6. INCOME TAX (continued)

Guangzhou Zhongkang Digital Technology Co., Ltd. (“Guangzhou Zhongkang Digital”) was accredited as a high and new technology enterprise (“HNTE”) in December 2022, and the certifications were valid for three years. For the six months ended 30 June 2023, Guangzhou Zhongkang Digital was entitled to a preferential PRC Corporate Income tax rate of 15% (30 June 2022: 25%).

Certain of the subsidiaries, which operate in Mainland China, are identified as Small and Micro Enterprises and were entitled to a preferential tax rate of 5% during the period.

The major components of the income tax expense of the Group during the period are analysed as follows:

6. 所得稅(續)

廣州中康數字科技有限公司(「廣州中康數字」)於2022年12月被認定為高新技術企業(「HNTE」)，證書有效期為三年。截至2023年6月30日止六個月，廣州中康數字享有15%的優惠中國企業所得稅稅率(2022年6月30日：25%)。

於期內，於中國內地營運的若干附屬公司被認定為小微企業，享有5%的優惠稅率。

本集團於期內的所得稅開支主要組成部分分析如下：

		For the six months ended 30 June 截至6月30日止六個月	
		2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元	2022 2022年 (Unaudited) (未經審核) RMB'000 人民幣千元
Current – Mainland China charge for the period	即期一期內扣除的中國內地稅項	3,403	127
Deferred tax	遞延稅項	(2,481)	(1,488)
Total tax charge/(credit) for the period	期內扣除/(抵免)的稅項總額	922	(1,361)

7. DIVIDENDS

On 29 March 2023, a final dividend for the year ended 31 December 2022 of HK\$3.98 cents per ordinary share, amounting to approximately RMB15,753,000, has been approved by the shareholders at the annual general meeting for the Company, which was paid in July 2023.

7. 股息

於2023年3月29日，本公司股東於股東週年大會上批准派發截至2022年12月31日止年度的末期股息每股普通股3.98港仙，共計約人民幣15,753,000元，已於2023年7月派付。

80 NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION
 中期簡明綜合財務資料附註

8. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic earnings per share amounts is based on the profit for the period attributable to ordinary equity holders of the parent. The weighted average number of shares has been retrospectively adjusted for the effect of the capitalisation issue (note 16) on the assumption that the capitalization issue had been completed on 1 January 2021.

The Group had no potentially dilutive ordinary shares in issue during the period.

The calculations of basic and diluted earnings per share are based on:

8. 母公司普通股權益持有人應佔每股盈利

每股基本盈利金額乃根據母公司普通股持有人應佔期內溢利計算。股份的加權平均數乃假設資本化發行(附註16)已於2021年1月1日完成，就資本化發行的影響追溯調整。

期內本集團並無潛在攤薄已發行普通股。

每股基本及攤薄盈利乃根據以下數據計算：

		For the six months ended 30 June	
		截至6月30日止六個月	
		2023	2022
		2023年	2022年
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
		RMB'000	RMB'000
		人民幣千元	人民幣千元
Earnings	盈利		
Profit attributable to ordinary equity holders of the parent, used in the basic and diluted earnings per share calculation	用於計算每股基本及攤薄盈利的母公司普通股持有人應佔溢利	47,833	3,860

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION
 中期簡明綜合財務資料附註

8. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT (continued) **8. 母公司普通股權益持有人應佔每股盈利(續)**

		Number of shares For the six months ended 30 June 股份數目 截至6月30日止六個月	
		2023 2023年 (Unaudited) (未經審核)	2022 2022年 (Unaudited) (未經審核)
Shares	股份		
Weighted average number of ordinary shares in issue used in the basic and diluted earnings per share calculation	用於計算每股基本及攤薄盈利的已發行普通股加權平均數	430,762,185	375,000,000

9. PROPERTY, PLANT AND EQUIPMENT **9. 物業、廠房及設備**

		30 June 2023 2023年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2022 2022年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Carrying amount at beginning of period/year	於期/年初的賬面值	4,383	4471
Additions	添置	1,594	2,855
Depreciation provided during the period/year	期/年內計提折舊	(1,242)	(2,659)
Disposals	出售	(2)	(284)
Carrying amount at end of period/year	於期/年末的賬面值	4,733	4,383

82 NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION
 中期簡明綜合財務資料附註

10. TRADE AND NOTES RECEIVABLES

10. 貿易應收款項及應收票據

		30 June 2023 2023年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2022 2022年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Trade receivables	貿易應收款項	83,447	92,028
Notes receivable	應收票據	2,004	6,287
Impairment	減值	(11,683)	(6,322)
		73,768	91,993

The Group's trading terms with its customers are mainly on credit. The credit terms granted generally ranged from 7 days to 120 days, depending on the specific payment terms in each contract. The Group seeks to maintain strict control over its outstanding receivables. Overdue balances are reviewed regularly by senior management. The Group does not hold any collateral or other credit enhancements over its trade receivable balances. Trade receivables are non-interest-bearing.

本集團與其客戶的貿易條款以信貸為主。所授出的信貸期一般介乎7日至120日，視乎各份合約的特定支付條款而定。本集團尋求維持嚴格控制其未償還應收款項。高級管理層定期檢討逾期結餘。本集團並未就貿易應收款項結餘持有任何抵押品或其他信用增強措施。貿易應收款項不計息。

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

10. TRADE AND NOTES RECEIVABLES (continued)

An ageing analysis of the trade receivables as at the end of the reporting period, based on the transaction dates and net of loss allowance, is as follows:

		30 June 2023 2023年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2022 2022年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Within 6 months	6個月內	42,797	66,345
6 to 12 months	6至12個月	22,219	11,084
1 to 2 years	1至2年	6,648	8,162
2 to 3 years	2至3年	100	115
		71,764	85,706

The movements in the loss allowance for impairment of trade receivables are as follows:

		30 June 2023 2023年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2022 2022年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
At beginning of period/year	於期／年初	6,322	4,541
Impairment losses, net	減值虧損淨額	5,361	2,678
Amount written off as uncollectible	因不可收回而撇銷的金額	-	(897)
At end of period/year	於期／年末	11,683	6,322

10. 貿易應收款項及應收票據(續)

於報告期末，貿易應收款項基於交易日期及扣除虧損撥備後的賬齡分析如下：

貿易應收款項的減值虧損撥備變動如下：

84 NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION
 中期簡明綜合財務資料附註

11. FINANCIAL ASSETS AT FAIR VALUE THROUGH PROFIT OR LOSS **11. 按公平值計入損益的金融資產**

	30 June 2023 2023年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2022 2022年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Unlisted investments, at fair value 非上市投資， 按公平值計值	46,797	2,098

The unlisted investments represented certain financial products issued by commercial banks in Mainland China. They were classified as financial assets at fair value through profit or loss as their contractual cash flows are not solely payments of principal and interest.

非上市投資指中國內地商業銀行發行的若干金融產品。由於該等投資的合約現金流量並非僅支付本金及利息，故被分類為按公平值計入損益的金融資產。

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION 85
 中期簡明綜合財務資料附註

12. CASH AND CASH EQUIVALENTS

12. 現金及現金等價物

		30 June 2023 2023年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2022 2022年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Cash and bank balances	現金及銀行結餘	37,005	246,798
Time deposits	定期存款	645,227	418,766
Less:	減：		
Current portion:	即期部分：		
Non-pledged time deposits with original maturity of over three months when required	於取得時原到期日長於三個月之無抵押定期存款	320,292	175,474
Non-Current portion:	非即期部分：		
Non-pledged time deposits with original maturity of over three months when required	於取得時原到期日長於三個月之無抵押定期存款	162,746	80,772
Cash and cash equivalents	現金及現金等價物	199,194	409,318
Denominated in:	以下列貨幣計值：		
RMB	人民幣	138,165	346,680
US\$	美元	60,654	61,919
HK\$	港元	375	719
		199,194	409,318

86 NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION 中期簡明綜合財務資料附註

12. CASH AND CASH EQUIVALENTS (continued)

The RMB is not freely convertible into other currencies, however, under Mainland China's Foreign Exchange Control Regulations and Administration of Settlement, and Sale and Payment of Foreign Exchange Regulations, the Group is permitted to exchange RMB for other currencies through banks authorised to conduct foreign exchange business.

Cash at banks earns interest at floating rates based on daily bank deposit rates. Time deposits are made for varying periods from one months to three years and earn interest at the fixed time deposit rates. The bank balances and time deposits are deposited with creditworthy banks with no recent history of default.

13. TRADE PAYABLES

An ageing analysis of the trade payables as at the end of the reporting period, based on the invoice date, is as follows:

Within 3 months	於3個月內
4 to 6 months	4至6個月
7 to 12 months	7至12個月
Over 12 months	12個月以上

Trade payables are non-interest-bearing and are normally settled within 90 days.

12. 現金及現金等價物(續)

人民幣不可自由兌換為其他貨幣，然而，根據中國內地《外匯管理條例》及《結匯、售匯及付匯管理規定》，本集團獲准透過獲授權進行外匯業務的銀行將人民幣兌換為其他貨幣。

銀行現金按基於每日銀行存款利率的浮動利率賺取利息。定期存款就一個月至三年的不同期間敘造，並按固定的定期存款利率賺取利息。銀行結餘及定期存款存入近期並無違約歷史的信譽良好的銀行。

13. 貿易應付款項

於報告期末，基於發票日期的貿易應付款項賬齡分析如下：

		30 June 2023 2023年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2022 2022年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Within 3 months	於3個月內	6,514	11,834
4 to 6 months	4至6個月	676	623
7 to 12 months	7至12個月	666	1,968
Over 12 months	12個月以上	1,133	240
		8,989	14,665

貿易應付款項為不計息，一般於90日內結清。

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION 87
 中期簡明綜合財務資料附註

14. OTHER PAYABLES AND ACCRUALS

14. 其他應付款項及應計費用

		30 June 2023 2023年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2022 2022年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Payroll payables	應付薪酬	15,197	27,887
Contract liabilities	合約負債	65,583	35,997
Tax payables other than income tax	應付稅項(所得稅除外)	6,337	7,225
Dividend payable	應付股息	15,753	-
Other payables	其他應付款項	765	3,030
		103,635	74,139

Contract liabilities include short-term advances received before the services are rendered.

合約負債包括提供服務前收取的短期預付款項。

15. COMMITMENTS

At the end of each of the reporting period, the Group did not have any significant commitments.

15. 承擔

於各報告期末，本集團並無任何重大承擔。

88 NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION
 中期簡明綜合財務資料附註

16. SHARE CAPITAL AND TREASURY SHARES 16. 股本及庫存股份

		30 June 2023 2023年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2022 2022年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Authorised:	法定：		
2,000,000,000 (2022: 2,000,000,000) ordinary shares of US\$0.01 each	2,000,000,000股(2022年： 2,000,000,000股)每股 面值0.01美元的普通股		
US\$'000	千美元	4,518	4,518
RMB'000	人民幣千元	30,384	30,384
Issued and fully paid:	已發行及繳足：		
451,770,000 (2022: 451,770,000) ordinary shares of US\$0.01 each	451,770,000股(2022年： 451,770,000股)每股面 值0.01美元的普通股		
US\$'000	千美元	4,518	4,518
RMB'000	人民幣千元	30,384	30,384

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

16. SHARE CAPITAL AND TREASURY SHARES (continued)

A summary of movements in the Company's share capital is as follows:

本公司股本的變動概要如下：

		Notes	Number of shares in issue 已發行 股份數目	Share capital 股本 RMB'000 人民幣千元	Treasury shares 庫存股份 RMB'000 人民幣千元
At 1 January 2022	於2022年1月1日		5,000,000	322	–
Initial public offering	首次公開發售	(a)	75,000,000	5,047	–
Capitalisation issue	資本化發行	(b)	370,000,000	24,896	–
Exercise of the over-allotment option	行使超額配股權	(c)	1,770,000	119	–
Shares repurchased	購回股份	(d)	–	–	(101,121)
At 31 December 2022 and 1 January 2023	於2022年12月31日 及2023年1月1日		451,770,000	30,384	(101,121)
Shares repurchased	購回股份	(e)	–	–	(5,876)
At 30 June 2023	於2023年6月30日		451,770,000	30,384	(106,997)

Notes:

附註：

(a) On 12 July 2022, 75,000,000 ordinary shares of par value US\$0.01 each were issued at a price of HK\$5.36 per share in connection with the Company's initial public offering ("Listing Date"). The proceeds of US\$750,000 (equivalent to RMB5,047,000) representing the par value, were credited to the Company's share capital. The remaining proceeds of approximately US\$47,466,000 (equivalent to approximately RMB319,399,000) before listing expenses were credited to the share premium account.

(a) 於2022年7月12日，本公司進行首次公開發售時（「上市日期」），按每股5.36港元的價格發行75,000,000股每股面值0.01美元的普通股。相當於面值的所得款項750,000美元（相等於人民幣5,047,000元）已計入本公司的股本。餘下所得款項約47,466,000美元（相等於約人民幣319,399,000元）（未扣除上市開支）已計入股份溢價賬。

90 NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION
 中期簡明綜合財務資料附註

16. SHARE CAPITAL AND TREASURY SHARES (continued) **16. 股本及庫存股份(續)**

- (b) Pursuant to the written resolutions of the shareholders of the Company passed on 27 April 2022 and 22 June 2022, a total of 370,000,000 shares of US\$0.01 each were allotted and issued at par value to the shareholders whose names were on the register of members of the Company as at the date of the passing of the resolutions, on a pro rata basis, and such shares were allotted and issued by way of capitalisation of US\$3,700,000 (approximately RMB24,896,000) from the Company's share premium account on the Listing Date.
- (b) 根據本公司股東於2022年4月27日及2022年6月22日通過的書面決議案，合共370,000,000股每股面值0.01美元的股份已按面值按比例配發及發行予於通過決議案當日名列本公司股東名冊的股東，而該等股份乃於上市日期從本公司股份溢價賬中將3,700,000美元(約人民幣24,896,000元)撥充資本之方式配發及發行。
- (c) On 4 August 2022, 1,770,000 over-allotment ordinary shares of par value US\$0.01 each were issued at a price of HK\$5.36 per share. The proceeds of US\$17,700 (equivalent to approximately RMB119,000) representing the par value, were credited to the Company's share capital. The remaining proceeds of approximately US\$1,191,000 (equivalent to approximately RMB8,055,000) before listing expenses were credited to the share premium account.
- (c) 於2022年8月4日，1,770,000股每股面值0.01美元的超額分配普通股按每股5.36港元的價格發行。相當於面值的所得款項17,700美元(相等於約人民幣119,000元)已計入本公司股本。餘下所得款項約1,191,000美元(相等於約人民幣8,055,000元)(未扣除上市開支)已計入股份溢價賬。
- (d) The Company purchased 20,585,500 of its shares on the Hong Kong Stock Exchange at a total consideration of approximately HK\$112,865,000 (equivalent to approximately RMB101,121,000) for a share award scheme.
- (d) 本公司就股份獎勵計劃，按總代價約112,865,000港元(相等於約人民幣101,121,000元)在香港聯交所購回20,585,500股股份。
- (e) The Company purchased 1,166,000 of its shares on the Hong Kong Stock Exchange at a total consideration of approximately HK\$6,185,000 (equivalent to approximately RMB5,876,000) for a share award scheme.
- (e) 本公司就股份獎勵計劃，按總代價約6,185,000港元(相等於約人民幣5,876,000元)在香港聯交所購回1,166,000股股份。

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

17. RELATED PARTY TRANSACTIONS

The Group's principal related parties are as follows:

17. 關聯方交易

本集團主要關聯方如下：

Company 公司	Relationship with the Company 與本公司的關係
Wellmark Link Limited 盈連有限公司	Shareholder 股東
WLF Investment Holdings Limited	Shareholder 股東
Ms. Wu Meirong 吳美容女士	Intermediate shareholder 中間股東
Mr. Wu Yushu 吳鬱抒先生	Director and key management personnel 董事及主要管理人員
Ms. Wang Lifang 王莉芳女士	Director and key management personnel 董事及主要管理人員
Mr. Fu Haitao 付海濤先生	Non-executive director and key management personnel 非執行董事及主要管理人員
Ms. Yi Xuhui 易旭暉女士	Key management personnel 主要管理人員
Mr. Tang Keke* 唐珂軻先生*	Key management personnel 主要管理人員
Mr. Su Caihua 蘇才華先生	Key management personnel 主要管理人員
Mr. Li Junguo 李俊國先生	Key management personnel 主要管理人員
Jiangxi Yaoshunshun Medicine Company Limited **	An associate (before 29 August 2022)
江西藥順順藥業有限公司**	一家聯營公司(2022年8月29日前)
Guangzhou Zhonghui Medical Technology Company Limited	An entity influenced significantly by a director, Mr Wu Yushu
廣州中惠醫療科技有限公司	受董事吳鬱抒先生重大影響的實體
Guangzhou Yishutong Technology Company Limited	An entity influenced significantly by a director, Mr Wu Yushu
廣州易數通科技有限公司	受董事吳鬱抒先生重大影響的實體

* Mr. Tang Keke resigned as a key management personnel on 4 May 2023.

* 唐珂軻先生於2023年5月4日辭任主要管理人員。

** The investment in Jiangxi Yaoshunshun Medicine Company Limited was disposed of by a subsidiary of the Company to a third party on 29 August 2022.

** 本公司一間附屬公司已於2022年8月29日將於江西藥順順藥業有限公司的投資出售予一名第三方。

92 NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION
 中期簡明綜合財務資料附註

17. RELATED PARTY TRANSACTIONS 17. 關聯方交易(續)
 (continued)

(a) The Group had the following transactions with related parties during the period:

(a) 期內本集團與關聯方之間有以下交易：

		For the six months ended 30 June 截至6月30日止六個月	
		2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元	2022 2022年 (Unaudited) (未經審核) RMB'000 人民幣千元
Sales to related parties*:	向關聯方銷售*：		
Jiangxi Yaoshunshun Medicine Company Limited	江西藥順順藥業有限公司	-	60
Guangzhou Yishutong Technology Company Limited	廣州易數通科技有限公司	59	-
Purchases of services from related parties**:	向關聯方購買服務**：		
Guangzhou Yishutong Technology Company Limited	廣州易數通科技有限公司	172	-
Guangzhou Zhonghui Medical Technology Company Limited	廣州中惠醫療科技有限公司	619	177
Depreciation of right-of-use assets***:	使用權資產折舊***：		
Ms. Wu Meirong	吳美容女士	285	-
Interest expense on lease liabilities***:	租賃負債的利息開支***：		
Ms. Wu Meirong	吳美容女士	32	-

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION 93
 中期簡明綜合財務資料附註

17. RELATED PARTY TRANSACTIONS (continued)

(a) The Group had the following transactions with related parties during the period: (continued)

- * The sales to the related parties were made according to the prices and terms mutually agreed between the parties.
- ** The purchases from the related parties were made according to the prices and terms mutually agreed between the parties.
- *** The depreciation of right-of-use assets and interest expense on lease liabilities relate to the leases of the offices from related party pursuant to the terms of the agreements signed between the Group and the related party.

(b) Outstanding balances with related parties:

17. 關聯方交易(續)

(a) 期內本集團與關聯方之間有以下交易：(續)

- * 向關聯方銷售乃根據雙方共同協定的價格及條款作出。
- ** 向關聯方的購買乃根據雙方共同協定的價格及條款作出。
- *** 使用權資產折舊及租賃負債的利息開支乃關於根據本集團與關聯方簽訂的協議條款從關聯方租賃辦公室。

(b) 與關聯方的未償還結餘：

	30 June 2023 2023年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2022 2022年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Due to Guangzhou Zhonghui Medical Technology Company Limited* 應付廣州中惠醫療科技有限公司的款項*	157	355

- * The amounts due to the related party were trade in nature, unsecured, interest-free and repayable on demand.

- * 應付關聯方款項屬貿易性質、無抵押、不計息及按要求償還。

94 NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION
 中期簡明綜合財務資料附註

17. RELATED PARTY TRANSACTIONS 17. 關聯方交易(續)
 (continued)

(c) Compensation of key management personnel of the Group:

(c) 本集團主要管理人員的薪酬：

		For the six months ended 30 June 截至6月30日止六個月	
		2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元	2022 2022年 (Unaudited) (未經審核) RMB'000 人民幣千元
Salaries, allowances and benefits in kind	薪金、津貼及實物福利	1,543	2,854
Pension scheme contributions	退休金計劃供款	19	25
Total compensation paid to key management personnel	已付主要管理人員的薪酬總額	1,562	2,879

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION
中期簡明綜合財務資料附註**18. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS**

Management has assessed that the fair values of cash and cash equivalents, trade and notes receivables, trade payables, financial assets included in prepayments, other receivables and other assets, financial liabilities included in other payables and accruals, the current portion of lease liabilities and amounts due to a related party approximate to their carrying amounts largely due to the short term maturities of these instruments.

The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

The fair values of the non-current portion of lease liabilities has been calculated by discounting the expected future cash flows using rates currently available for instruments with similar terms, credit risk and remaining maturities. The changes in fair value as a result of the Group's own non-performance risk for lease liabilities as at the end of the reporting period were assessed to be insignificant.

18. 金融工具公平值及公平值層級

據管理層評估，現金及現金等價物、貿易應收款項及應收票據、貿易應付款項、計入預付款項、其他應收款項及其他資產的金融資產、計入其他應付款項及應計費用的金融負債、租賃負債流動部分及應付一名關聯方款項之公平值與其賬面值相若，乃主要由於該等工具到期日較短所致。

金融資產及負債的公平值以自願交易方（強迫或清盤出售除外）當前交易中該工具之可交易金融入賬。

租賃負債非流動部分的公平值已按使用擁有類似條款、信貸風險及餘下年期之工具現時可用比率貼現之預期未來現金流量計算。於報告期末，本集團本身就租賃負債的不履約風險產生的公平值變動被評估為不重大。

96 NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION
 中期簡明綜合財務資料附註

18. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (continued)

The Group invests in unlisted investments, which represent certain financial products issued by commercial banks in Mainland China. The Group has estimated the fair value of these unlisted investments by using a discounted cash flow the valuation model based on the market interest rates of instruments with similar terms and risks.

The following tables illustrate the fair value measurement hierarchy of the Group's financial instruments:

**Assets measured at fair value:
 30 June 2023**

18. 金融工具公平值及公平值層級 (續)

本集團投資於非上市投資，該等投資指中國內地商業銀行發行的若干金融產品。本集團根據具有類似條款及風險的工具的市場利率，使用貼現現金流量估值模型估計該等非上市投資的公平值。

下表列示本集團金融工具之公平值計量層級：

**按公平值計量的資產：
 2023年6月30日**

		Fair value measurement using 使用以下方式的公平值計量			
		Quoted prices in active markets 於活躍市場 的報價 (Level 1) (第1級) RMB'000 人民幣千元	Significant observable inputs 重大可觀察 輸入數據 (Level 2) (第2級) RMB'000 人民幣千元	Significant unobservable inputs 重大不可觀 察輸入數據 (Level 3) (第3級) RMB'000 人民幣千元	Total 總計 RMB'000 人民幣千元
Financial assets at fair value through profit or loss	按公平值計入損益 的金融資產	-	46,797	-	46,797

97

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION
中期簡明綜合財務資料附註

18. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (continued)
Assets measured at fair value: (continued)

31 December 2022

18. 金融工具公平值及公平值層級 (續)
按公平值計量的資產：(續)

2022年12月31日

	Fair value measurement using 使用以下方式的公平值計量			Total 總計
	Quoted prices in active markets 於活躍市場 的報價 (Level 1) (第1級) RMB'000 人民幣千元	Significant observable inputs 重大可觀察 輸入數據 (Level 2) (第2級) RMB'000 人民幣千元	Significant unobservable inputs 重大不可觀 察輸入數據 (Level 3) (第3級) RMB'000 人民幣千元	
Financial assets at fair value through profit or loss	-	2,098	-	2,098

The Group did not have any financial liabilities measured at fair value as at the end of the reporting period.

於報告期末，本集團並無任何按公平值計量的金融負債。

During the reporting period, there were no transfers of fair value measurements between Level 1 and Level 2 and no transfers into or out of Level 3 for both financial assets and financial liabilities.

於報告期內，就金融資產及金融負債而言，第1級與第2級之間並無公平值計量轉移，亦無轉入或轉出第3級。

98 DEFINITIONS

釋義

“AI”		artificial intelligence
「AI」	指	人工智能
“AI-MDT”		artificial intelligence multi-disciplinary treatment
「AI-MDT」	指	人工智能多學科治療
“Articles of Association”		the articles of association of the Company (as amended from time to time)
「組織章程細則」	指	本公司的組織章程細則(經不時修訂)
“Audit Committee”		the audit committee of the Board
「審核委員會」	指	董事會轄下審核委員會
“Big Data Artificial Intelligence Enterprise”		enterprise approved for registration in the database in accordance with the “Notice of the Guangzhou Municipal Industry and Information Technology Bureau on Carrying Out Regular Registration of Big Data/Artificial Intelligence Enterprises in 2021-2022”
「大數據人工智能企業」	指	根據《廣州市工業和信息化局關於開展2021-2022年大數據／人工智能企業常態化入庫登記工作的通知》審核批准登記入庫的企業
“CG Code”		the Corporate Governance Code as set out in Appendix 14 to the Listing Rules
「企業管治守則」	指	上市規則附錄十四所載企業管治守則

“China” or “PRC”		the People’s Republic of China, but for the purpose of this interim report only and except where the context requires otherwise, references in this interim report to “China” or “PRC” do not include Hong Kong, the Macau Special Administrative Region and Taiwan
「中國」	指	中華人民共和國，但僅就本中期報告而言及另外按文義所需，凡在本中期報告內提述「中國」，均不包括香港、澳門特別行政區及台灣
“CMH”		the cooperation under the CMH Cooperation Agreements
「CMH」	指	CMH合作協議所指的合作
“CMH Cooperation Agreement(s)”		the agreements with retail pharmacies in the PRC in respect of data cooperation arrangements. Under the agreements, retail pharmacies provide retail data on a monthly basis, while the Group provides data insights and reports to the retail pharmacies in return
「CMH合作協議」	指	就數據合作安排與中國零售藥店訂立的協議。根據該等協議，零售藥店每月提供零售數據，而本集團則向零售藥店提供數據洞察及報告
“Company”		Sinohealth Holdings Limited, an exempted company with limited liability incorporated in the Cayman Islands on 4 March 2019 and registered as a non-Hong Kong company under Part 16 of the Companies Ordinance on 7 July 2021
「本公司」	指	中康控股有限公司，一家於2019年3月4日在開曼群島註冊成立的獲豁免有限公司，並根據公司條例第16部於2021年7月7日註冊為非香港公司
“connected person(s)”		has the meaning ascribed to it in the Listing Rules
「關連人士」	指	具上市規則賦予的涵義

100 DEFINITIONS

釋義

“CPEO”		Pharmaceutical Enterprises Co-operation and Development Organisation, our event held for healthcare industry players
「西普會」	指	產業前景大會，我們為健康產業參與者舉辦的活動
“Director(s)”		the director(s) of the Company
「董事」	指	本公司董事
“Eligible Participant”		any individual being an Employee Participant, Related Entity Participant or Service Provider, provided such person is not a connected person of the Group
「合資格參與者」	指	任何為僱員參與者、相關實體參與者或服務供應商的個人，惟該人士並非本集團的關連人士
“Employee Participant”		employees (including full-time employees and part-time employees) of the Company or any of its Subsidiaries (including persons who are granted awards under the Scheme as an inducement to enter into employment contracts with these companies)
「僱員參與者」	指	本公司或其任何附屬公司(包括作為與該等公司簽訂僱傭合約的獎勵而根據計劃獲授獎勵的人士)的僱員(包括全職及兼職僱員)
“Global Offering”		the Hong Kong public offering and international offering of the Shares
「全球發售」	指	股份的香港公开发售及國際發售

“GMV”		gross merchandise volume, being the total value of products sold in a given period, which is equal to the selling price per product multiplied by the number of products sold
「GMV」	指	商品交易總值，即於特定期間內已售產品的總值，相等於每件產品的售價乘以已售產品數目
“Group” or “We”		the Company and its subsidiaries
「本集團」或「我們」	指	本公司及其附屬公司
“Headquarter Enterprise”		enterprise with substantial contribution to the economic and social development of Guangzhou as determined in accordance with the Notice of the General Office of the Guangzhou Municipal People’s Government on the Issuance of Several Measures to Promote the Development of Headquarter Economy in Guangzhou
「總部企業」	指	根據《廣州市人民政府辦公廳關於印發廣州市促進總部經濟發展若干措施的通知》評定的對廣州市經濟社會發展作出較大貢獻的企業
“Healthcare Industry Ecological Platform”		our platform for the events established for healthcare industry players, including CPEO, PHCF, MASC and other small-scale events we organize throughout the year
「健康產業生態平台」	指	我們為健康產業參與者舉辦的活動平台，包括西普會、西鼎會、美思會及我們於全年組織的其他小規模活動

102 DEFINITIONS

釋義

“High and New Technology Enterprise”		high and new technology enterprise recognised in accordance with the Administrative Measures for the Determination of High and New Tech Enterprises published by the Ministry of Science and Technology, the Ministry of Finance and the State Administration of Taxation
「高新技術企業」	指	根據科技部、財政部及國家稅務總局頒佈的《高新技術企業認定管理辦法》認定的高新技術企業
“HK\$”		Hong Kong dollars, the lawful currency of Hong Kong
「港元」	指	香港法定貨幣港元
“HKFRS”		Hong Kong Financial Reporting Standards issued by the Hong Kong Institute of Certified Public Accountants
「香港財務報告準則」	指	香港會計師公會頒佈的香港財務報告準則
“Hong Kong”		the Hong Kong Special Administrative Region of the PRC
「香港」	指	中國香港特別行政區
“Innovative Small and Medium-sized Enterprise”		enterprise with innovative capability as determined in accordance with the Notice of the Department of Industry and Information Technology of Guangdong Province on Organizing and Carrying Out Assessment of Innovative Small and Medium-sized Enterprises and Identification and Review of Specialised and Innovative Small and Medium-sized Enterprises for 2022
「創新性中小企業」	指	根據《廣東省工業和信息化廳關於組織開展2022年創新型中小企業評價、專精特新中小企業認定和覆核工作的通知》評定的具有創新能力的企業
“ISO”		International Organisation for Standardisation
「ISO」	指	國際標準化組織

“Listing Date”		12 July 2022, on which the Shares were listed on the Stock Exchange and from which dealings in the Shares were permitted to commence on the Stock Exchange
「上市日期」	指	2022年7月12日，即股份在聯交所上市及股份獲准自該日起開始在聯交所買賣的日期
“Listing Rules”		the Rules Governing the Listing of Securities on the Stock Exchange
「上市規則」	指	聯交所證券上市規則
“MASC”		Marketing and Sales Conference, our event held for healthcare industry players
「美思會」	指	零售銷售大會，我們為健康產業參與者舉辦的活動
“Model Code”		Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix 10 to the Listing Rules
「標準守則」	指	上市規則附錄十所載上市發行人董事進行證券交易的標準守則
“Nomination Committee”		the nomination committee of the Board
「提名委員會」	指	董事會轄下的提名委員會
“PaaS layer”		the secondary development on the PaaS architecture, which realizes the standardized, software-based, modularized and service-oriented operation of the professional analytical capabilities and knowledge spectrum of the healthcare industry through big data management, algorithmic models, artificial intelligence and application development, as well as the provision of generic services such as process engines and authority settings
「PaaS層」	指	在PaaS架構上進行二次開發，通過大數據管理、演算法模型、人工智慧、應用開發實現大健康產業專業分析能力和知識圖譜的標準化、軟件化、模塊化和服務化，以及提供流程引擎、權限設置等通用服務

104 DEFINITIONS

釋義

“Partnering Pharmacies”		retail pharmacies with whom we enter into CMH Cooperation Agreements or SIC Services Agreements
「合作藥店」	指	本集團與之訂立CMH合作協議或SIC服務協議的零售藥店
“pharmaceutical retailer”		pharmaceutical retail chain(s) generally comprising ten or more retail stores
「醫藥零售企業」	指	一般由十家或以上零售店舖組成的連鎖醫藥零售企業
“PHCF”		Pharma & Healthcare Conference and Fair, our event held for healthcare industry players
「西鼎會」	指	商品交易大會，我們為健康產業參與者舉辦的活動
“Prospectus”		the prospectus of the Company dated 28 June 2022 in connection with the Global Offering
「招股章程」	指	本公司日期為2022年6月28日有關全球發售的招股章程
“real-world study”		collecting patient-related data in a real-world environment, and through analysis, obtaining clinical evidence of the use value and potential benefits or risks of medical products. The main type of research is observational research, which can also be clinical trials
「真實世界研究」	指	在真實世界環境下收集與患者有關的數據，通過分析，獲得醫療產品的使用價值及潛在獲益或風險的臨床證據，主要研究類型是觀察性研究，也可以是臨床試驗
“Remuneration Committee”		the remuneration committee of the Board
「薪酬委員會」	指	董事會轄下的薪酬委員會

“Reporting Period”		six months ended 30 June 2023
「報告期」	指	截至2023年6月30日止六個月
“RMB”		Renminbi, the lawful currency of China
「人民幣」	指	中國法定貨幣人民幣
“SaaS”		software as a service, a cloud-based software licensing and delivery model in which software and associated data are centrally hosted
「SaaS」	指	軟件即服務，一種雲端軟件授權及交付模式，軟件及相關數據可在其中集中托存
“Scheme Rules”		the rules of the Share Award Scheme, as may be amended from time to time
「計劃規則」	指	股份獎勵計劃規則(經不時修訂)
“SFO”		the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)
「證券及期貨條例」	指	香港法例第571章證券及期貨條例
“Share(s)”		ordinary share(s) of nominal value of HK\$0.01 each in the share capital of the Company
「股份」	指	本公司股本中每股面值0.01港元的普通股
“Share Award Scheme”		the share award scheme adopted by the Company on 5 December 2022
「股份獎勵計劃」	指	本公司於2022年12月5日採納的股份獎勵計劃

106 DEFINITIONS

釋義

“Share Option Scheme”		the share option scheme adopted by the Company on 27 April 2022
「購股權計劃」	指	本公司於2022年4月27日採納的購股權計劃
“Shareholder(s)”		holder(s) of the Share(s)
「股東」	指	股份持有人
“Shenzhen Data Exchange”		Shenzhen Data Exchange Co., Ltd. (深圳數據交易所有限公司), a state-owned limited liability company established by the Shenzhen Municipal Party Committee and Municipal Government to firmly implement the spirit of the central government’s document of “Implementation Plan for the Comprehensive Reform Pilot Project of Building an Exemplary Demonstration Zone of Socialism with Chinese Characteristics in Shenzhen (2020-2025)”, and deepen the task of reforming the market-oriented allocation of data elements, with the goal of constructing a national data trading platform.
「深圳數據交易所」	指	深圳數據交易所有限公司，是一家由深圳市委市政府堅定落實中央《深圳建設中國特色社會主義先行示範區綜合改革試點實施方案(2020-2025年)》文件精神、深化數據要素市場化配置改革任務的關鍵舉措，以建設全國性數據交易平台為目標而設立的國有有限責任公司
“SIC”		one of the SaaS products in the Group’s Smart Retail Cloud business segment for pharmaceutical retailers, empowering customers, pharmacy staff, categories and store operations of pharmaceutical retailers through intelligent systems, professional operations and insights into the entire industry chain and market
「SIC」	指	本集團智慧零售雲業務版塊一款SaaS產品，面向醫藥零售企業，通過智能系統、專業運營、全產業鏈及市場洞察，為醫藥零售企業顧客、店員、品類、門店運營賦能

"SIC Services Agreement(s)"		the agreement(s) with the Group's SIC user(s) governing (i) the provision of SIC, and (ii) data cooperation arrangement
「SIC服務協議」	指	就約定(i)本集團提供SIC；及(ii)數據合作安排而與本集團的SIC用戶訂立的協議
"Sinohealth Information"		Guangzhou Sinohealth Information Co., Ltd (廣州中康資訊股份有限公司), a joint stock company with limited liability established in the PRC on 20 December 2007 and deemed to be a wholly-owned subsidiary of the Group pursuant to the Contractual Arrangements
「中康資訊」	指	廣州中康資訊股份有限公司，一家於2007年12月20日在中國成立的股份有限公司，根據合約安排被視為本集團的全資附屬公司
"Specialised and Innovative Small and Medium-sized Enterprise"		enterprise with specialised, refined, distinctive and innovative capabilities recognised in accordance with the Measures for Selection of Specialised and Innovative Small and Medium-sized Enterprises of the Department of Industry and Information Technology of Guangdong Province
「專精特新中小企業」	指	根據《廣東省工業和信息化廳專精特新中小企業遴選辦法》認定的具有專業化、精細化、特色化和創新能力的企業
"Stock Exchange"		The Stock Exchange of Hong Kong Limited
「聯交所」	指	香港聯合交易所有限公司
"TB"		trillion bytes, a unit of measurement of computer storage capacity
「TB」	指	萬億字節，衡量計算機存儲能力的計量單位
"Top List of the Most Promising Artificial Intelligence Enterprises in Guangzhou"		the top list of the most promising artificial intelligence enterprises in Guangzhou under the guidance of Guangzhou Science and Technology Bureau and selected by Guangzhou Technology Financial Group
「廣州最具發展潛力人工智慧企業榜單」	指	在廣州市科學技術局指導及由廣州科技金融集團評選的廣州最具發展潛力人工智慧企業榜單

108 DEFINITIONS

釋義

“Trust”		the trust constituted by the Trust Deed
「信託」	指	由信託契據構成的信託
“Trust Deed”		a trust deed to be entered into between the Company as settlor and the Trustee as trustee of the Trust (as restated, supplemented and amended from time to time)
「信託契據」	指	本公司(作為授予人)與信託人(作為信託的信託人)將予訂立的信託契據(經不時重列、補充及修訂)
“Trustee”		Futu Trustee Limited, a professional trustee appointed under the Trust Deed to act as trustee of the Trust, and any additional or replacement trustees, being the trustee or trustees for the time being of the trusts declared in the Trust Deed
「受託人」	指	富途信託有限公司，為根據信託契據被任命為信託受託人的專業受託人，以及任何額外或替代受託人，作為信託契據中宣佈的信託當時的受託人
“US\$”		United States dollars, the lawful currency of the United States of America
「美元」	指	美國法定貨幣美元
“Zhongkang Technology”		Guangzhou Zhongkang Digital Technology Co., Ltd. (廣州中康數字科技有限公司), a company established in the PRC with limited liability on 8 April 2019, which is directly owned as to 100% by Sinohealth Technology Limited, an indirect wholly-owned subsidiary of the Group
「中康科技」	指	廣州中康數字科技有限公司，一家於2019年4月8日在中國成立的有限公司，由中康健康科技有限公司直接持有100%權益，為本集團的間接全資附屬公司
“%”		per cent
「%」	指	百分比

Sinohealth Hldg
中康控股

中康控股有限公司

Sinohealth Holdings Limited